Introduction {#s2}
============

The World Health Organization (WHO) estimates that there were 655,000 malaria deaths in 2010, with 86% occurring in children under 5 y [@pmed.1001619-World1]. Malaria deaths are declining with the massive scaling up of control measures, of which insecticide-treated bed nets (ITNs) are a major component. ITNs reduce deaths in children [@pmed.1001619-Lengeler1] and provide personal protection to the user, and at scale they provide community-wide protection by reducing the number of infective mosquitoes in the vicinity where ITNs are used [@pmed.1001619-Jones1],[@pmed.1001619-Okia1]. Between 2008 and 2010, 254 million ITNs were supplied to countries in sub-Saharan Africa, and the proportion of African households in possession of a net rose from 3% in 2000 to 50% by 2010 [@pmed.1001619-World2]. Nets, when in good condition and used correctly, are effective, simple to use, easy to deliver to rural communities, and cost-effective when used in highly endemic malarious areas [@pmed.1001619-Okumu1]. On account of their low mammalian toxicity, speed of action, and high insecticidal activity, pyrethroids [@pmed.1001619-Briet1] are the only insecticide class recommended by the WHO for use in ITNs [@pmed.1001619-Hougard1]. ITNs are effective with the African vectors *Anopheles gambiae* s.s. and *An. funestus* in part because these species are endophagic (feed indoors) and endophilic (rest indoors after feeding). Aside from their insecticidal activity, pyrethroids also exert an excito-repellency effect, which can lead to fewer mosquitoes entering a home (deterrence) where ITNs are used, or can cause disrupted blood feeding and premature exit of mosquitoes from the home (induced exophily) [@pmed.1001619-Okumu2]. Because of the excito-repellency property of ITNs, these nets retain their personal protection properties for users even after the nets become holed [@pmed.1001619-Darriet1].

The emergence and spread of insecticide resistance to all four classes of public health insecticides (pyrethroids, organochlorines, organophosphates, and carbamates) threatens the effectiveness of ITNs and indoor residual house spraying. Currently, 27 countries in sub-Saharan Africa have reported pyrethroid resistance in *Anopheles* vectors [@pmed.1001619-Ranson1]. The real figure could very well be higher, as a lack of in-country resistance monitoring prevents accurate assessment. Because of their pyrethroid dependency, ITNs are especially vulnerable to insecticide resistance, as unlike indoor residual house spraying there are no readily available alternative insecticides. To prevent amplifying pyrethroid resistance, the WHO recommends that pyrethroid insecticides should not be used for indoor residual house spraying in areas with high long-lasting insecticide-treated bed net (LLIN) coverage [@pmed.1001619-World1]. In a recent study the extensive deployment and use of LLINs was blamed in part for selecting resistance in *Anopheles* vectors in Senegal, where malaria morbidity also increased [@pmed.1001619-Trape1]. The threat of resistance has led the WHO and members of the Roll Back Malaria Partnership to produce the "Global Plan for Insecticide Resistance Management in Malaria Vectors", which stresses the urgency with which this problem needs to be addressed [@pmed.1001619-World3].

Insecticide resistance takes multiple forms: target-site resistance, metabolic resistance, and cuticular resistance. Target-site resistance to pyrethroids in *An. gambiae* and *An. arabiensis* is underpinned by a non-silent point mutation (either L1014F or L1014S) in the sodium channel gene, which is referred to as the knock-down resistance (*kdr*) genotype [@pmed.1001619-MartinezTorres1],[@pmed.1001619-Ranson2]. Target-site resistance prevents the successful binding of the insecticide molecule to sodium channels on the nerve membranes. Metabolic resistance is caused by the activity of three large multi- gene families (cytochrome P450s, glutathione transferases, and carboxylesterases) that are able to metabolise or sequester the insecticide, thereby preventing it from reaching its target [@pmed.1001619-Hemingway1]. It is becoming clear that the cytochrome P450s are responsible for the majority of cases of metabolic resistance, with a secondary role for the glutathione transferases [@pmed.1001619-Djouaka1]--[@pmed.1001619-Mitchell1]. There is also preliminary evidence that cuticular resistance may be a contributing factor, but this aspect requires further analysis [@pmed.1001619-Djouaka1],[@pmed.1001619-Awolola1],[@pmed.1001619-Wood1]. As pyrethroids and the organochlorine insecticide DDT target the sodium channel protein, cross-resistance to both insecticides is common. There is evidence that phenotypic resistance and *kdr* frequency have increased following the introduction of ITNs in some areas [@pmed.1001619-Ndiath1],[@pmed.1001619-Norris1], which could nullify the effectiveness of ITNs [@pmed.1001619-Ranson3].

Policy makers and researchers debate whether these various forms of resistance are having an impact on the effectiveness of ITNs in malaria control. We carried out a systematic review of all relevant studies on human outcomes, but it became clear very quickly that there was an almost total absence of evidence to draw any conclusions on the impact of pyrethroid resistance on the efficacy of nets in decreasing disease transmission. So we turned to entomological studies: evidence of an effect of resistance on mosquitoes could be indicative of resistance having an impac on disease transmission. Our objective is to assess the effects of insecticide resistance in African anopheline mosquitoes on ITNs in terms of entomological outcomes in precise laboratory assays (cone tests), in laboratory tests with animals (tunnel tests), and in field trials with human volunteers as the attractants.

Methods {#s3}
=======

Inclusion Criteria {#s3a}
------------------

### Study design {#s3a1}

We included laboratory tests (cone tests and tunnel tests) and field trials using experimental huts (see [Box 1](#pmed-1001619-box002){ref-type="sec"} for details of types of studies included).

#### Box 1. Types of Studies Included {#s3a1a1}

##### Cone Test {#s3a1a1a}

**Methods:** Studies in the laboratory in which mosquitoes are placed inside a plastic cone that is attached to a net for three minutes; after net exposure the mosquitoes are placed in a holding container while entomological outcomes are measured [@pmed.1001619-World4].

**Outcomes:** Mosquito mortality after 24 h, percentage knock-down at 60 min, and time to 50% or 95% knock-down.

**Advantages:** Researchers can standardise confounding variables, such as mosquito species, sex, age, and blood feeding status. The number of mosquitoes used in the test is standardised.

##### Tunnel Test {#s3a1a1b}

**Methods:** Studies in a laboratory, using animal bait, such as a guinea pig, placed at one end of a specially constructed tunnel. A fixed number of mosquitoes are released at the other end of the tunnel, and they must pass through a holed ITN or UTN to reach the animal bait. The following morning, both live and dead mosquitoes, blood fed and non-blood fed, are collected and counted from both sides of the holed net. Live mosquitoes are monitored for a further 24 h to assess delayed mortality [@pmed.1001619-World4].

**Outcomes:** Deterrence (not passed through net), blood feeding, and mosquito mortality.

**Advantages:** As for cone test.

##### Field Trials {#s3a1a1c}

**Methods:** Studies in areas where mosquitoes breed. Volunteers sleep in experimental huts for a specific period under an ITN or an UTN, with one hut per person. The huts are identical in construction, and incorporate exit traps to catch wild mosquitoes entering and exiting the hut prematurely. Each morning of the trial, both live and dead mosquitoes, blood fed and non-blood fed, are collected and counted from both inside the hut and the exit traps. Live mosquitoes are monitored for a further 24 h to assess delayed mortality. Volunteers and nets are randomly allocated to huts at the start of the trial and are usually rotated to avoid bias. Often huts are cleaned between rotations to avoid cross-contamination of huts from the different treatment arms [@pmed.1001619-World4].

**Outcomes:** Deterrence, blood feeding, mosquito mortality, and induced exophily.

**Advantages:** Given that this method assesses the response of wild mosquitoes to human volunteers, it is a more realistic representation of how effective ITNs are in terms of entomological outcomes, compared with laboratory methods.

### Mosquito population {#s3a2}

Included African malaria vectors were *An. gambiae*, *An. arabiensis*, or *An. funestus*. We included laboratory studies that used established laboratory-colonised strains of mosquitoes with known resistance phenotype or genotype. Experimental hut study trials were included if they measured the resistance status of the wild mosquito populations at the time of the study by bioassays with our without *kdr* genotyping.

### Intervention {#s3a3}

We included studies that compared an ITN (conventionally treated bed net \[CTN\] or a LLIN) versus an untreated bed net (UTN). The CTNs (which require dipping into insecticide and which also require retreatment at least once a year) must have been impregnated with a WHO-recommended pyrethroid with the recommended formulation and dose (see [Table 1](#pmed-1001619-t001){ref-type="table"} for recommended impregnation regimens). The LLINs (which are factory-treated nets where the insecticide is incorporated within or bound around the net fibres) must have had either interim or full recommendation from the WHO (see [Table 2](#pmed-1001619-t002){ref-type="table"} for recommended LLINs).

10.1371/journal.pmed.1001619.t001

###### WHO-recommended pyrethroids for treatment of CTNs for vector control.

![](pmed.1001619.t001){#pmed-1001619-t001-1}

  Pyrethroid                       Formulation               Dosage[a](#nt101){ref-type="table-fn"}
  -------------------- ------------------------------------ ----------------------------------------
  Alpha-cypermethrin                  SC 10%                                 20--40
  Cyfluthrin                          EW 5%                                    50
  Deltamethrin          SC 1%; WT 25%; WT 25%+binderK-o^b^                   15--25
  Etofenprox                          EW 10%                                  200
  Lambda-cyhalothrin                 CS 2.5%                                 10--15
  Permethrin                          EC 10%                                200--500

Milligrams of active ingredient per square metre of netting.

K-O [Tab 1](#pmed-1001619-t001){ref-type="table"}-[2](#pmed-1001619-t002){ref-type="table"}-3.

CS, capsule suspension; EC, emulsifiable concentrate; EW, emulsion, oil in water; SC, suspension concentrate; WT, water dispersible tablet.

10.1371/journal.pmed.1001619.t002

###### WHO-recommended LLINs for vector control.

![](pmed.1001619.t002){#pmed-1001619-t002-2}

  Product Name                                                                               Product Type                                                                              Status of WHO Recommendation
  -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------
  DawaPlus 2.0                                                                     Deltamethrin coated on polyester                                                                              Interim
  Duranet                                                                 Alpha-cypermethrin incorporated into polyethylene                                                                      Interim
  Interceptor                                                                   Alpha-cypermethrin coated on polyester                                                                             Full
  LifeNet                                                                    Deltamethrin incorporated into polypropylene                                                                        Interim
  MAGNet                                                                  Alpha-cypermethrin incorporated into polyethylene                                                                      Interim
  Netprotect                                                                 Deltamethrin incorporated into polypropylene                                                                        Interim
  Olyset                                                                      Permethrin incorporated into polypropylene                                                                           Full
  OlysetPlus                                                       Permethrin and piperonyl butoxide incorporated into polyethylene                                                              Interim
  PermaNet 2.0                                                                     Deltamethrin coated on polyester                                                                                Full
  PermaNet 2.5                                                        Deltamethrin coated on polyester with strengthened border                                                                  Interim
  PermaNet 3.0    Combination: deltamethrin coated on polyester with strengthened border (side panels) and deltamethrin and piperonyl butoxide incorporated into polyethylene (roof)             Interim
  Royal Sentry                                                            Alpha-cypermethrin incorporated into polyethylene                                                                      Interim
  Yorkool LN                                                                       Deltamethrin coated on polyester                                                                                Full

### Outcomes {#s3a4}

Included outcomes were blood feeding, mosquito mortality, deterrence (reduction in the number of mosquitoes found in experimental huts), induced exophily (number of mosquitoes found in the exit trap of experimental huts), not passed though net (measure of deterrence in tunnel test), percent knock-down at 60 min, time to 50% knock-down, and time to 95% knock-down [@pmed.1001619-World4] ([Table 3](#pmed-1001619-t003){ref-type="table"}).

10.1371/journal.pmed.1001619.t003

###### Measured outcomes appropriate for the different types of study.

![](pmed.1001619.t003){#pmed-1001619-t003-3}

  Outcome                                                                                                                                                                                     Description                                                                                                                                                                     Laboratory Methods   Field Method: Experimental Hut Trial  
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- -------------------------------------- ---
  Blood feeding                                                                                 A measure of the number of mosquitoes that have fed within a hut or in a tunnel during a lab test. Indicates how effective an ITN is in protecting the person sleeping under it (personal protection).                                                                                                              √                     √
  Mosquito mortality        Measured as the number of mosquitoes killed following exposure to an ITN or UTN, either immediate death or delayed death (24 h following exposure). Measured as a proportion of the total number of mosquitoes found within a hut or placed in tunnel/cone during a lab test. Indicates how effective an ITN is at directly killing mosquitoes.           √                             √                     √
  Induced exophily                                                                  Measured as the proportion of mosquitoes found in exit traps, which indicates an attempt to prematurely exit the hut. Indicates how effective an ITN is in protecting the person sleeping under the net (personal protection).                                                                                                                        √
  Deterrence                                                            A reduction in the number of mosquitoes entering a hut using an ITN relative to the number of mosquitoes found in a control hut using an UTN. Indicates how effective an ITN is in protecting the person sleeping under the net (personal protection).                                                                                                            √
  Not pass through net                                 Equivalent to deterrence in hut trials; measured as the number of mosquitoes that do not pass through a holed ITN to reach an animal bait relative to an UTN in a control test. Indicates the potential effectiveness an ITN could have in protecting the person sleeping under the net.                                                                     √                    
  Knock-down at 60 min                                                                                                          The number of mosquitoes that are knocked down (the inability of a mosquito to fly or stand) within 60 min following exposure to a net.                                                                                                               √                                                  
  Time to 50% knock-down                                                                                                                                           The time taken to knock down 50% of mosquitoes used in the test.                                                                                                                                                   √                                                  
  Time to 95% knock-down                                                                                                                                           The time taken to knock down 95% of mosquitoes used in the test.                                                                                                                                                   √                                                  

Search Strategy {#s3b}
---------------

The search period was from 1 January 1980 to 17 May 2013 or later. We searched the following databases for relevant studies: MEDLINE (from 1 January 1980 to 31 December 2013) and Cochrane Central Register of Controlled Trials, Science Citation Index Expanded, Social Sciences Citation Index, African Index Medicus, and CAB Abstracts (from 1 January 1980 to 17 May 2013). There was no language restriction (see [Table S1](#pmed.1001619.s024){ref-type="supplementary-material"} for the search terms used).

We also searched the following conference proceedings: First MIM Pan-African Malaria Conference, Senegal, 6--9 January 1997; Second MIM Pan-African Malaria Conference, South Africa, 15--19 March 1999; Third MIM Pan-African Malaria Conference, Tanzania, 17--22 November 2002; Fourth MIM Pan-African Malaria Conference, Cameroon, 13--18 November 2005; Fifth MIM Pan-African Malaria Conference, Nairobi, 2--6 November 2009; American Society of Tropical Medicine and Hygiene 59th Annual Meeting, Atlanta, Georgia, 3--7 November 2010; American Society of Tropical Medicine and Hygiene 60th Annual Meeting, Philadelphia, Pennsylvania, 4--8 December 2011; and American Society of Tropical Medicine and Hygiene 61^st^ Annual Meeting, Atlanta, Georgia, 11--15 November 2012.

Study Selection {#s3c}
---------------

Two authors (C. S. and A. A. E.) independently screened the search results for potentially relevant studies and retrieved the corresponding full articles. C. S. and A. A. E. independently assessed the articles for eligibility using a standardised form ([Table S2](#pmed.1001619.s025){ref-type="supplementary-material"}). Discrepancies between the eligibility results were resolved by discussion. Study investigators were contacted for clarification if the eligibility of a particular study was unclear. Multiple publications from the same study were identified, and if eligible, the original study was taken forward for inclusion.

Data Extraction {#s3d}
---------------

C. S. and A. A. E. independently extracted data from all included studies into a data extraction form. Missing or unclear outcome data were requested from the study investigators. For dichotomous outcomes for the ITN and UTN groups, the number of mosquitoes experiencing the outcome and the total number of mosquitoes were extracted ([Tables S3](#pmed.1001619.s026){ref-type="supplementary-material"}--[S5](#pmed.1001619.s028){ref-type="supplementary-material"}). For continuous outcomes, we extracted the mean and standard deviation when possible. For deterrence, the total number of mosquitoes was extracted for the ITN and UTN groups. A sub-sample of 10% of the studies was randomly selected to assess the performance of the duplicate extraction processes by C. S. and A. A. E. Differences between the two extraction processes were examined, and no serious discrepancies were found. The data extracted by C. S. were used in all analyses.

Stratification of Resistance {#s3e}
----------------------------

The WHO classifies mosquitoes as susceptible to insecticides if, after exposure to a diagnostic dose, there is ≥98% mortality, and as resistant to insecticides if there is ≤90% mortality; mortality between 97% and 90% requires the confirmation of resistance genes for mosquitoes to be classified as resistant [@pmed.1001619-World5]. Characterisation of resistance across studies was not consistent, as some studies used bioassays, others used *kdr* genotyping, and some used a combination of both. We therefore developed a composite classification system to allow us to categorise the insecticide resistance status of mosquitoes in three broad groups (low, moderate, and high), based on phenotypic resistance measured using bioassay mortality data and/or *kdr* frequency ([Table 4](#pmed-1001619-t004){ref-type="table"}). The alleles for *kdr* are presented as a frequency or percentage.

10.1371/journal.pmed.1001619.t004

###### Stratification of mosquito resistance constructed for this study based on either percent mortality from WHO bioassay data and/or *kdr* frequency.

![](pmed.1001619.t004){#pmed-1001619-t004-4}

  Resistance Status    Percent Bioassay Mortality    *kdr* Frequency (Percent)
  ------------------- ----------------------------- ---------------------------
  **High**                \<25 (low mortality)           \>80 (high *kdr*)
                          \<25 (low mortality)           \<25 (low *kdr*)
  **Moderate**         25--80 (moderate mortality)    25--80 (moderate *kdr*)
                       25--80 (moderate mortality)       \<25 (low *kdr*)
  **Low**                 \>80 (high mortality)          \<25 (low *kdr*)
  **Unclear**             \<25 (low mortality)           \<25 (low *kdr*)

Risk of Bias Assessment {#s3f}
-----------------------

C. S. assessed the risk of bias of each included study. We developed a quality assessment tool that used four criteria for tunnel and cone tests: (1) comparability of mosquitoes in ITN and UTN groups (all female, age matched, and non-blood fed), (2) observers blinded, (3) complete outcome data, and (4) raw data reported for ITN and UTN groups.

For experimental hut trials we developed seven criteria: (1) comparability of mosquitoes in ITN and UTN huts, (2) collectors blinded, (3) sleepers blinded, (4) raw data reported for ITN and UTN groups, (5) ITNs randomly allocated to huts, (6) ITNs rotated, and (7) sleepers rotated. For all criteria, we made a judgement of high, low, or unclear risk of bias.

For hut trials, we generated an additional set of variables to assess variability in the design and execution of the studies, called "rigor of implementation". The criteria assessed included (1) nets being washed according to WHO protocol, (2) cleaning of huts before the trial and between rotations to avoid cross-contamination of huts from the different treatment arms and to remove any insects that may have been missed during collections, (3) whether ITNs were tested either chemically or using bioassays to assess the insecticide impregnation efficacy and residual activity (applicable to CTNs), and (4) whether male mosquitoes were excluded from the analysis. We also reported how each study measured resistance in the wild mosquito populations: whether phenotypic resistance was measured by bioassays and/or *kdr* genotyping (and the number of mosquito screened for *kdr*), and whether metabolic resistance was measured.

Data Analysis {#s3g}
-------------

Analyses were carried out in Review Manager 5. We stratified the analyses by study design and the resistance status of the mosquito population ([Table 4](#pmed-1001619-t004){ref-type="table"}). Dichotomous outcomes were summarised using the RD; therefore, results are generalisable only to situations where the UTN group event rate is comparable to those observed here. When the same study compared multiple ITNs, the event rate in the UTN group was split to ensure each mosquito was included in the analysis only once.

The results of studies were pooled using meta-analysis when possible. DerSimonian and Laird random effects models were used when heterogeneity was detected; otherwise, a fixed effects Mantel-Haenszel method was applied. It is worth noting that a random effects meta-analysis awards more weight to smaller studies than a fixed effects meta-analysis, and the weights for each study tend to equality as the between-trial variance increases.

Assessment of Heterogeneity {#s3h}
---------------------------

Data that could not be presented in forest plots were tabulated. Heterogeneity was assessed by visually inspecting the forest plots to detect overlapping confidence intervals, applying the chi-squared test with a *p*-value of 0.10 used to indicate statistical significance, and implementing the *I* ^2^ test statistic, with a value of 50% indicating a moderate level of heterogeneity. Of course, such assessments of heterogeneity are influenced by the number of included studies and should be interpreted with caution.

Heterogeneity was substantive and common in all the analyses, and we sought explanations through a variety of pre-specified subgroup analyses. Subgroups included net type, type and concentration of insecticide, and whether the net was washed or not. We carried out sensitivity analyses by examining the effects when analyses were restricted to hut trials that had a low risk of bias (i.e., ITNs randomly allocated to huts, ITNs rotated, sleepers rotated). Reporting biases were explored using funnel plots. We calculated the confidence intervals for the *I* ^2^ statistic using the method described in [@pmed.1001619-Thorlund1].

Results {#s4}
=======

Search Results {#s4a}
--------------

[Figure 1](#pmed-1001619-g001){ref-type="fig"} displays the review profile. Database searches recovered 1,107 records, from which three duplicates were removed. Searching other sources did not yield any potentially relevant records. After screening the 1,104 records, 914 records were excluded. Of the remaining 73 records, 55 records were excluded (see [Figure 1](#pmed-1001619-g001){ref-type="fig"} for exclusion reasons). The remaining 25 records [@pmed.1001619-Okia1],[@pmed.1001619-Okumu1],[@pmed.1001619-Okumu2],[@pmed.1001619-Asidi1]--[@pmed.1001619-Oxborough2] described 60 separate studies (a study is defined as a comparison that has a distinct control UTN arm). Results of 53 of the 60 studies were combined in a meta-analysis; the results of five studies are described in [Tables 5](#pmed-1001619-t005){ref-type="table"} and [6](#pmed-1001619-t006){ref-type="table"}; and two studies did not report useable data.

![Flow diagram of the study selection process.](pmed.1001619.g001){#pmed-1001619-g001}

10.1371/journal.pmed.1001619.t005

###### Results from cone tests comparing LLIN or CTN versus UTN for time to 50% and 95% knock-down.

![](pmed.1001619.t005){#pmed-1001619-t005-5}

  Study                                                     Intervention (All versus UTN)     Net Washed    Mosquito Species (Strain)    Resistance Status    ITN    UTN                   
  ------------------------------------------------------ ----------------------------------- ------------ ----------------------------- ------------------- ------- ------ ----- ---- ---- -----
  Hodjati 1999 (KWA 1 d) [@pmed.1001619-Hodjati1]            CTN permethrin 500 mg/m^2^           No        *An. gambiae* s.s. (KWA)            Low          11.7    ---    110   NA   NA   33
  Hodjati 1999 (KWA 10 d fed) [@pmed.1001619-Hodjati1]       CTN permethrin 500 mg/m^2^           No        *An. gambiae* s.s. (KWA)            Low          10.4    ---    110   NA   NA   33
  Mahama 2007 (Kisumu) [@pmed.1001619-Mahama1]                    LLIN PermaNet 2.0               No       *An. gambiae* s.s. (Kisumu)          Low            5      10    50    NA   NA   50
  Fane 2012 [@pmed.1001619-Fane1]                         CTN alpha-cypermethrin 40 mg/m^2^       No       *An. gambiae* s.s. (Kisumu)          Low          \<3.0    26    400   NA   NA   400
  Hodjati 1999 (RSP 1 d) [@pmed.1001619-Hodjati1]            CTN permethrin 500 mg/m^2^           No        *An. gambiae* s.s. (RSP)           High          23.2    ---    132   NA   NA   33
  Hodjati 1999 (RSP 10 d) [@pmed.1001619-Hodjati1]           CTN permethrin 500 mg/m^2^           No        *An. gambiae* s.s. (RSP)           High          16.6    ---    77    NA   NA   33
  Mahama 2007 (VKPR) [@pmed.1001619-Mahama1]                      LLIN PermaNet 2.0               No        *An. gambiae* s.s. (VKPR)          High          16.4    32.7   100   NA   NA   100

KDT~50~, time to knock-down of 50% of the mosquitoes; KDT~95~, time to knock-down of 95% of the mosquitoes; NA, not applicable.

10.1371/journal.pmed.1001619.t006

###### Results from tunnel tests comparing CTN versus UTN for mosquito mortality, blood feeding, and not passed though net.

![](pmed.1001619.t006){#pmed-1001619-t006-6}

  Study                                                   Intervention (All versus UTN)              Net Washed    Mosquito Species (Strain)    Resistance Status   Mortality (Percent)   Blood Feeding (Percent)   Not Passed though Net (Percent)                    
  -------------------------------------------- ---------------------------------------------------- ------------ ----------------------------- ------------------- --------------------- ------------------------- --------------------------------- ------------ ---- ------------
  Oxborough 2009a [@pmed.1001619-Oxborough1]     CTN deltamethrin 25 mg/m^2^ (on polyester nets)         No       *An. gambiae* s.s. (Kisumu)          Low                  87                  Not stated                        28                  Not stated   53   Not stated
  Oxborough 2009b [@pmed.1001619-Oxborough1]    CTN deltamethrin 25 mg/m^2^ (on polyethylene nets)       No       *An. gambiae* s.s. (Kisumu)          Low                  97                  Not stated                        11                  Not stated   67   Not stated
  Oxborough 2009c [@pmed.1001619-Oxborough1]       CTN deltamethrin 25 mg/m^2^ (on cotton nets)          No       *An. gambiae* s.s. (Kisumu)          Low                  85                  Not stated                        28                  Not stated   58   Not stated
  Oxborough 2009d [@pmed.1001619-Oxborough1]       CTN deltamethrin 25 mg/m^2^ (on nylon nets)           No       *An. gambiae* s.s. (Kisumu)          Low                  63                  Not stated                        50                  Not stated   46   Not stated

The updated MEDLINE search (May--December 2013) recovered 291 records, of which two records were assessed for eligibility. They were subsequently excluded for not meeting the study design inclusion criteria and for not characterising resistance in the mosquito populations at the time of the study.

Characteristics of Included Studies {#s4b}
-----------------------------------

The 60 included studies included cone tests (*n* = 25), tunnel tests (*n* = 11), and experimental hut trials (*n* = 24).

### Cone tests {#s4b1}

The 25 included cone test studies made 60 comparisons. Characteristics for each comparison are given in [Table 7](#pmed-1001619-t007){ref-type="table"}. UTNs were compared against unwashed and washed CTNs and LLINs.

10.1371/journal.pmed.1001619.t007

###### Study characteristics of the included cone tests.

![](pmed.1001619.t007){#pmed-1001619-t007-7}

  Study                                                                   Mosquito Species (Strain/Origin)                                                                  Intervention (All versus UTN)                                                 ITN Washed   Resistance Status        Bioassay Percent Mortality (Insecticide)        *kdr* Frequency (Mutation)    Metabolic Resistance    Measured Outcomes          
  ------------------------------------------------------ ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------ ------------------- ---------------------------------------------------- ---------------------------- ------------------------ ------------------- --- --- ---
  Darriet 1998 (Kisumu)a [@pmed.1001619-Darriet2]                      *An. gambiae* s.s. (Kisumu, lab strain)                                                               CTN deltamethrin 25 mg/m^2^                                                      No              Low          100% (permethrin 0.25%), 100% (deltamethrin 0.25%)           Not stated                 Not stated                 Y           Y   N   N
  Darriet 1998 (Kisumu)b [@pmed.1001619-Darriet2]                      *An. gambiae* s.s. (Kisumu, lab strain)                                                          CTN permethrin 500 mg/m^2^, 225 holes                                                 No              Low          100% (permethrin 0.25%), 100% (deltamethrin 0.25%)           Not stated                 Not stated                 Y           Y   N   N
  Darriet 1998 (YFO)a [@pmed.1001619-Darriet2]            *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)                                            CTN deltamethrin 25 mg/m^2^, 225 holes                                                 No             High                     67.0% (deltamethrin 0.025%)                     \>80% (L1014F)               Not stated                 Y           Y   N   N
  Darriet 1998 (YFO)b [@pmed.1001619-Darriet2]            *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)                                             CTN permethrin 500 mg/m^2^, 225 holes                                                 No             High                       15.9% (permethrin 0.25%)                      \>80% (L1014F)               Not stated                 Y           Y   N   N
  Etang 2004 (Kisumu) [@pmed.1001619-Etang1]                           *An. gambiae* s.s. (Kisumu, lab strain)                                                               CTN permethrin 500 mg/m^2^                                                       No              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Etang 2004 (OC-Lab) [@pmed.1001619-Etang1]                                 *An. gambiae* (lab strain)                                                                      CTN permethrin 500 mg/m^2^                                                       No            Unclear                            Not stated                               Not stated           Elevated P450 activity           Y           Y   N   N
  Fane 2012 [@pmed.1001619-Fane1]                                      *An. gambiae* s.s. (Kisumu, lab strain)                                                            CTN alpha-cypermethrin 40 mg/m^2^                                                   No              Low                              Not stated                               Not stated                 Not stated                 Y           N   Y   Y
  Gimnig 2005 (Kisumu)a [@pmed.1001619-Gimnig1]                        *An. gambiae* s.s. (Kisumu, lab strain)                                                                       LLIN Olyset                                                              No              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Gimnig 2005 (Kisumu)b [@pmed.1001619-Gimnig1]                        *An. gambiae* s.s. (Kisumu, lab strain)                CTN K-O [Tab 1](#pmed-1001619-t001){ref-type="table"}-[2](#pmed-1001619-t002){ref-type="table"}-3 deltamethrin 25 mg/m^2^       No              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Hodjati 1999 (KWA 1 d) [@pmed.1001619-Hodjati1]                       *An. gambiae* s.s. (KWA, lab strain)                                                                 CTN permethrin 500 mg/m^2^                                                       No              Low                              Not stated                               Not stated                 Not stated                 Y           N   Y   N
  Hodjati 1999 (KWA 10 d) [@pmed.1001619-Hodjati1]                      *An. gambiae* s.s. (KWA, lab strain)                                                                 CTN permethrin 500 mg/m^2^                                                       No              Low                              Not stated                               Not stated                 Not stated                 Y           N   Y   N
  Hodjati 1999 (KWA 10 d fed) [@pmed.1001619-Hodjati1]                  *An. gambiae* s.s. (KWA, lab strain)                                                                 CTN permethrin 500 mg/m^2^                                                       No              Low                              Not stated                               Not stated                 Not stated                 Y           N   Y   N
  Hodjati 1999 (RSP 1 d) [@pmed.1001619-Hodjati1]                       *An. gambiae* s.s. (RSP, lab strain)                                                                 CTN permethrin 500 mg/m^2^                                                       No             High                              Not stated                               Not stated                 Not stated                 Y           N   Y   N
  Hodjati 1999 (RSP 10 d) [@pmed.1001619-Hodjati1]                      *An. gambiae* s.s. (RSP, lab strain)                                                                 CTN permethrin 500 mg/m^2^                                                       No             High                              Not stated                               Not stated                 Not stated                 Y           N   Y   N
  Hodjati 1999 (RSP 10 d fed) [@pmed.1001619-Etang1]                    *An. gambiae* s.s. (RSP, lab strain)                                                                 CTN permethrin 500 mg/m^2^                                                       No             High                              Not stated                               Not stated                 Not stated                 Y           N   Y   N
  Mahama 2007 (Kisumu) [@pmed.1001619-Mahama1]                         *An. gambiae* s.s. (Kisumu, lab strain)                                                                    LLIN PermaNet 2.0                                                           No              Low                              Not stated                               Not stated                 Not stated                 Y           N   Y   Y
  Mahama 2007 (VKPR) [@pmed.1001619-Mahama1]                            *An. gambiae* s.s. (VKPR, lab strain)                                                                     LLIN PermaNet 2.0                                                           No             High                              Not stated                               Not stated                 Not stated                 Y           N   Y   Y
  Malima 2009 (cone) [@pmed.1001619-Malima2]                   *An. gambiae* s.s. (Muheza, Tanzania, wild population)                                                        CTN deltamethrin 25 mg/m^2^                                                      No              Low                       100% (permethrin 0.75%)                         Not stated                 Not stated                 Y           Y   N   N
  Koudou 2011 (Kisumu)a [@pmed.1001619-Koudou1]                        *An. gambiae* s.s. (Kisumu, lab strain)                                                                    LLIN PermaNet 3.0                                                           No              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Koudou 2011 (Kisumu)b [@pmed.1001619-Koudou1]                        *An. gambiae* s.s. (Kisumu, lab strain)                                                                    LLIN PermaNet 3.0                                                          Yes              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Koudou 2011 (Kisumu)c [@pmed.1001619-Koudou1]                        *An. gambiae* s.s. (Kisumu, lab strain)                                                                    LLIN PermaNet 2.0                                                           No              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Koudou 2011 (Kisumu)d [@pmed.1001619-Koudou1]                        *An. gambiae* s.s. (Kisumu, lab strain)                                                                    LLIN PermaNet 2.0                                                          Yes              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Koudou 2011 (Kisumu)e [@pmed.1001619-Koudou1]                        *An. gambiae* s.s. (Kisumu, lab strain)                                                               CTN deltamethrin 25 mg/m^2^                                                     Yes              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Koudou 2011 (YFO)a [@pmed.1001619-Koudou1]              *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)                                                       LLIN PermaNet 3.0                                                           No             High                      10.6% (deltamethrin 0.05%)                     \>80% (L1014F)               Not stated                 Y           Y   N   N
  Koudou 2011 (YFO)b [@pmed.1001619-Koudou1]              *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)                                                       LLIN PermaNet 3.0                                                          Yes             High                      10.6% (deltamethrin 0.05%)                     \>80% (L1014F)               Not stated                 Y           Y   N   N
  Koudou 2011 (YFO)c [@pmed.1001619-Koudou1]              *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)                                                       LLIN PermaNet 2.0                                                           No             High                      10.6% (deltamethrin 0.05%)                     \>80% (L1014F)               Not stated                 Y           Y   N   N
  Koudou 2011 (YFO)d [@pmed.1001619-Koudou1]              *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)                                                       LLIN PermaNet 2.0                                                          Yes             High                      10.6% (deltamethrin 0.05%)                     \>80% (L1014F)               Not stated                 Y           Y   N   N
  Koudou 2011 (YFO)e [@pmed.1001619-Koudou1]              *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)                                                  CTN deltamethrin 25 mg/m^2^                                                     Yes             High                      10.6% (deltamethrin 0.05%)                     \>80% (L1014F)               Not stated                 Y           Y   N   N
  Malima 2008 (cone)a [@pmed.1001619-Malima1]                          *An. gambiae* s.s. (Kisumu, lab strain)                                                                       LLIN Olyset                                                              No              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Malima 2008 (cone)b [@pmed.1001619-Malima1]                          *An. gambiae* s.s. (Kisumu, lab strain)                                                            CTN alpha-cypermethrin 20 mg/m^2^                                                   No              Low                              Not stated                               Not stated                 Not stated                 Y           Y   N   N
  Okia 2013 (Kisumu)a [@pmed.1001619-Okia1]                            *An. gambiae* s.s. (Kisumu, lab strain)                                                                       LLIN Olyset                                                              No              Low          100% (permethrin 0.75%), 100% (deltamethrin 0.05%)           Not stated                 Not stated                 Y           N   N   N
  Okia 2013 (Kisumu)b [@pmed.1001619-Okia1]                            *An. gambiae* s.s. (Kisumu, lab strain)                                                                    LLIN Interceptor                                                            No              Low          100% (permethrin 0.75%), 100% (deltamethrin 0.05%)           Not stated                 Not stated                 Y           N   N   N
  Okia 2013 (Kisumu)c [@pmed.1001619-Okia1]                            *An. gambiae* s.s. (Kisumu, lab strain)                                                                     LLIN Netprotect                                                            No              Low          100% (permethrin 0.75%), 100% (deltamethrin 0.05%)           Not stated                 Not stated                 Y           N   N   N
  Okia 2013 (Kisumu)d [@pmed.1001619-Okia1]                            *An. gambiae* s.s. (Kisumu, lab strain)                                                                    LLIN PermaNet 2.0                                                           No              Low          100% (permethrin 0.75%), 100% (deltamethrin 0.05%)           Not stated                 Not stated                 Y           N   N   N
  Okia 2013 (Kisumu)e [@pmed.1001619-Okia1]                            *An. gambiae* s.s. (Kisumu, lab strain)                                                                    LLIN PermaNet 3.0                                                           No              Low          100% (permethrin 0.75%), 100% (deltamethrin 0.05%)           Not stated                 Not stated                 Y           N   N   N
  Okia 2013 (Kanugu)a [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Kanugu, Uganda, wild population)                                                                 LLIN Olyset                                                              No           Moderate         68% (permethrin 0.75%), 97% (deltamethrin 0.05%)          36.7% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Kanugu)b [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Kanugu, Uganda, wild population)                                                              LLIN Interceptor                                                            No           Moderate         68% (permethrin 0.75%), 97% (deltamethrin 0.05%)          36.7% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Kanugu)c [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Kanugu, Uganda, wild population)                                                               LLIN Netprotect                                                            No           Moderate         68% (permethrin 0.75%), 97% (deltamethrin 0.05%)          36.7% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Kanugu)d [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Kanugu, Uganda, wild population)                                                              LLIN PermaNet 2.0                                                           No           Moderate         68% (permethrin 0.75%), 97% (deltamethrin 0.05%)          36.7% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Kanugu)e [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Kanugu, Uganda, wild population)                                                              LLIN PermaNet 3.0                                                           No           Moderate         68% (permethrin 0.75%), 97% (deltamethrin 0.05%)          36.7% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Lira)a [@pmed.1001619-Okia1]                        *An. gambiae* s.s. (Lira, Uganda, wild population)                                                                  LLIN Olyset                                                              No           Moderate         60% (permethrin 0.75%), 71% (deltamethrin 0.05%)          33.5% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Lira)b [@pmed.1001619-Okia1]                        *An. gambiae* s.s. (Lira, Uganda, wild population)                                                               LLIN Interceptor                                                            No           Moderate         60% (permethrin 0.75%), 71% (deltamethrin 0.05%)          33.5% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Lira)c [@pmed.1001619-Okia1]                        *An. gambiae* s.s. (Lira, Uganda, wild population)                                                                LLIN Netprotect                                                            No           Moderate         60% (permethrin 0.75%), 71% (deltamethrin 0.05%)          33.5% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Lira)d [@pmed.1001619-Okia1]                        *An. gambiae* s.s. (Lira, Uganda, wild population)                                                               LLIN PermaNet 2.0                                                           No           Moderate         60% (permethrin 0.75%), 71% (deltamethrin 0.05%)          33.5% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Lira)e [@pmed.1001619-Okia1]                        *An. gambiae* s.s. (Lira, Uganda, wild population)                                                               LLIN PermaNet 3.0                                                           No           Moderate         60% (permethrin 0.75%), 71% (deltamethrin 0.05%)          33.5% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Tororo)a [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Tororo, Uganda, wild population)                                                                 LLIN Olyset                                                              No           Moderate         53% (permethrin 0.75%), 66% (deltamethrin 0.05%)          35.4% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Tororo)b [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Tororo, Uganda, wild population)                                                              LLIN Interceptor                                                            No           Moderate         53% (permethrin 0.75%), 66% (deltamethrin 0.05%)          35.4% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Tororo)c [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Tororo, Uganda, wild population)                                                               LLIN Netprotect                                                            No           Moderate         53% (permethrin 0.75%), 66% (deltamethrin 0.05%)          35.4% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Tororo)d [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Tororo, Uganda, wild population)                                                              LLIN PermaNet 2.0                                                           No           Moderate         53% (permethrin 0.75%), 66% (deltamethrin 0.05%)          35.4% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Tororo)e [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Tororo, Uganda, wild population)                                                              LLIN PermaNet 3.0                                                           No           Moderate         53% (permethrin 0.75%), 66% (deltamethrin 0.05%)          35.4% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Wakiso)a [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Wakiso, Uganda, wild population)                                                                 LLIN Olyset                                                              No           Moderate         90% (permethrin 0.75%), 94% (deltamethrin 0.05%)          36.6% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Wakiso)b [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Wakiso, Uganda, wild population)                                                              LLIN Interceptor                                                            No           Moderate         90% (permethrin 0.75%), 94% (deltamethrin 0.05%)          36.6% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Wakiso)c [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Wakiso, Uganda, wild population)                                                               LLIN Netprotect                                                            No           Moderate         90% (permethrin 0.75%), 94% (deltamethrin 0.05%)          36.6% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Wakiso)d [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Wakiso, Uganda, wild population)                                                              LLIN PermaNet 2.0                                                           No           Moderate         90% (permethrin 0.75%), 94% (deltamethrin 0.05%)          36.6% (L1014S)               Not stated                 Y           N   N   N
  Okia 2013 (Wakiso)e [@pmed.1001619-Okia1]                     *An. gambiae* s.s. (Wakiso, Uganda, wild population)                                                              LLIN PermaNet 3.0                                                           No           Moderate         90% (permethrin 0.75%), 94% (deltamethrin 0.05%)          36.6% (L1014S)               Not stated                 Y           N   N   N
  Okumu 2012a [@pmed.1001619-Okumu1]                         *An. arabiensis* (colony established from wild population)                                                            LLIN Icon Life                                                             No              Low                  100% (DDT 4%), \>90% (pyrethroids)                   Not stated                 Not stated                 Y           N   N   N
  Okumu 2012b [@pmed.1001619-Okumu1]                         *An. arabiensis* (colony established from wild population)                                                              LLIN Olyset                                                              No              Low                  100% (DDT 4%), \>90% (pyrethroids)                   Not stated                 Not stated                 Y           N   N   N
  Okumu 2012c [@pmed.1001619-Okumu1]                         *An. arabiensis* (colony established from wild population)                                                           LLIN PermaNet 2.0                                                           No              Low                  100% (DDT 4%), \>90% (pyrethroids)                   Not stated                 Not stated                 Y           N   N   N
  Winkler 2012a [@pmed.1001619-Winkler1]                               *An. gambiae* s.s. (Kisumu, lab strain)                                                   CTN Icon Maxx lambda-cyhalothrin (polyethylene net)                                          No              Low                              Not stated                               Not stated                 Not stated                 Y           N   N   N
  Winkler 2012b [@pmed.1001619-Winkler1]                               *An. gambiae* s.s. (Kisumu, lab strain)                                                    CTN Icon Maxx lambda-cyhalothrin (polyester net)                                            No              Low                              Not stated                               Not stated                 Not stated                 Y           N   N   N

KD, percent knock-down at 60 min; KDT~50~, time to knock-down of 50% of the mosquitoes; KDT~95~, time to knock-down of 95% of the mosquitoes; MM, mosquito mortality; OC-Lab, OCEAC Laboratory strain; YFO, Yaokoffikro.

Fifty-seven comparisons used *An. gambiae* s.s. mosquitoes, whilst three were of *An. arabiensis*. Overall, 29 comparisons used laboratory-reared mosquito strains (Kisumu, VKPR, OC-Lab, KWA, and RSP strains), and 28 comparisons used wild field-caught mosquitoes from Yaokoffikro (Côte d\'Ivoire), Muheza (Tanzania), and localities in Uganda. Three comparisons used recently colonised *An. arabiensis* mosquitoes that were originally collected from the Ulanga District of Tanzania.

Based on the reported WHO bioassay percent mortalities and *kdr* frequencies, 28 comparisons were carried out with mosquitoes with low resistance, 20 comparisons with moderately resistant mosquitoes, and 11 comparisons with highly resistant mosquitoes; resistance was unclear for one comparison. Only one comparison measured metabolic resistance.

For the risk of bias assessment, all comparisons reported comparability of ITN and UTN mosquito groups, but it was unclear in all studies whether observers were blinded ([Table S6](#pmed.1001619.s029){ref-type="supplementary-material"}). No comparison reported incomplete outcome data. Fifteen comparisons reported raw data for ITN and UTN groups, the remaining 45 did not.

### Tunnel tests {#s4b2}

The 11 included tunnel test studies made 20 comparisons. UTNs were compared against unwashed CTNs and LLINs. Characteristics for each comparison are given in [Table 8](#pmed-1001619-t008){ref-type="table"}. All comparisons used *An. gambiae* mosquitoes (the number of mosquitoes used varied from 200 to 592). Three comparisons used wild field-caught mosquitoes from Yaokoffikro (Côte d\'Ivoire) and Muheza (Tanzania) in their assessment, whilst 17 comparisons used laboratory-reared mosquito strains (Kisumu, VKPR, Kisumu/VKPR hybrids, Tola, and Kou strains). Based on the reported WHO bioassay percent mortalities and *kdr* frequencies, 12 comparisons were carried out with mosquitoes with low resistance, six comparisons used highly resistant mosquitoes, and resistance was moderate for two comparisons. No comparison measured metabolic resistance.

10.1371/journal.pmed.1001619.t008

###### Study characteristics of the included tunnel tests.

![](pmed.1001619.t008){#pmed-1001619-t008-8}

  Study                                                                        Mosquito Species (Strain/Origin)                              Intervention (All versus UTN)              Net Washed   Resistance Status                   Resistance Testing                       Measured Outcomes                           
  ----------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------- ------------ ------------------- ---------------------------------------------------- --------------------------- ------------ --- --- ---
  Chandre 2000 (L1 Kisumu) [@pmed.1001619-Chandre1]                         *An. gambiae* s.s. (Kisumu, lab strain)                            CTN permethrin 250 mg/m^2^                   No              Low                        98% (permethrin 0.25%)                        Not stated           Not stated   Y   Y   Y
  Chandre 2000 (L1 Kou) [@pmed.1001619-Chandre1]                                *An. gambiae* (Kou, lab strain)                                CTN permethrin 250 mg/m^2^                   No             High                        0% (permethrin 0.25%)                        100% (L1014F)         Not stated   Y   Y   Y
  Chandre 2000 (L1 Tola) [@pmed.1001619-Chandre1]                            *An. gambiae* s.s. (Tola, lab strain)                             CTN permethrin 250 mg/m^2^                   No             High                              Not stated                             100% (L1014F)         Not stated   Y   Y   Y
  Chandre 2000 (L2 Kisumu) [@pmed.1001619-Chandre1]                         *An. gambiae* s.s. (Kisumu, lab strain)                            CTN permethrin 500 mg/m^2^                   No              Low                        98% (permethrin 0.25%)                        Not stated           Not stated   Y   Y   N
  Chandre 2000 (L2 YFO)a [@pmed.1001619-Chandre1]              *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)               CTN permethrin 250 mg/m^2^                   No             High                              Not stated                            94.4% (L1014F)         Not stated   Y   Y   N
  Chandre 2000 (L2 YFO)b [@pmed.1001619-Chandre1]              *An. gambiae* s.s. (Yaokoffikro, Côte d\'Ivoire, wild population)               CTN permethrin 500 mg/m^2^                   No             High                              Not stated                            94.4% (L1014F)         Not stated   Y   Y   N
  Corbel 2004 (Kisumu/VKPR hybrid)a [@pmed.1001619-Corbel1]             *An. gambiae* (Kisumu/VKPR hybrid, lab strain)                         CTN permethrin 250 mg/m^2^                   No           Moderate                            Not stated                       RS (frequency not stated)   Not stated   Y   Y   N
  Corbel 2004 (Kisumu/VKPR hybrid)b [@pmed.1001619-Corbel1]             *An. gambiae* (Kisumu/VKPR hybrid, lab strain)                         CTN permethrin 500 mg/m^2^                   No           Moderate                            Not stated                       RS (frequency not stated)   Not stated   Y   Y   N
  Corbel 2004 (Kisumu)a [@pmed.1001619-Corbel1]                             *An. gambiae* s.s. (Kisumu, lab strain)                            CTN permethrin 250 mg/m^2^                   No              Low                              Not stated                              Not stated           Not stated   Y   Y   N
  Corbel 2004 (Kisumu)b [@pmed.1001619-Corbel1]                             *An. gambiae* s.s. (Kisumu, lab strain)                            CTN permethrin 500 mg/m^2^                   No              Low                              Not stated                              Not stated           Not stated   Y   Y   N
  Corbel 2004 (VKPR)a [@pmed.1001619-Corbel1]                                *An. gambiae* s.s. (VKPR, lab strain)                             CTN permethrin 250 mg/m^2^                   No             High                              Not stated                       RR (frequency not stated)   Not stated   Y   Y   N
  Corbel 2004 (VKPR)b [@pmed.1001619-Corbel1]                                *An. gambiae* s.s. (VKPR, lab strain)                             CTN permethrin 500 mg/m^2^                   No             High                         Permethrin resistant                  RR (frequency not stated)   Not stated   Y   Y   N
  Malima 2008a [@pmed.1001619-Malima1]                                      *An. gambiae* s.s. (Kisumu, lab strain)                        CTN alpha-cypermethrin 20 mg/m^2^                No              Low          100% (deltamethrin 0.05%), 100% (permethrin 0.75%)            absent             Not stated   Y   Y   Y
  Malima 2008b [@pmed.1001619-Malima1]                                      *An. gambiae* s.s. (Kisumu, lab strain)                                   LLIN Olyset                           No              Low                       100% (permethrin 0.75%)                        Not stated           Not stated   Y   Y   Y
  Malima 2009 (tunnel) [@pmed.1001619-Malima2]                      *An. gambiae* s.s. (Muheza, Tanzania, wild population)                    CTN deltamethrin 25 mg/m^2^                   No              Low                       100% (permethrin 0.75%)                        Not stated           Not stated   Y   Y   Y
  Oxborough 2009a [@pmed.1001619-Oxborough1]                                *An. gambiae* s.s. (Kisumu, lab strain)                 CTN deltamethrin 25 mg/m^2^ (on polyester nets)         No              Low                              Not stated                              Not stated           Not stated   Y   Y   Y
  Oxborough 2009b [@pmed.1001619-Oxborough1]                                *An. gambiae* s.s. (Kisumu, lab strain)                CTN deltamethrin 25 mg/m^2^ (on polyethylene nets)       No              Low                              Not stated                              Not stated           Not stated   Y   Y   Y
  Oxborough 2009c [@pmed.1001619-Oxborough1]                                *An. gambiae* s.s. (Kisumu, lab strain)                   CTN deltamethrin 25 mg/m^2^ (on cotton nets)          No              Low                              Not stated                              Not stated           Not stated   Y   Y   Y
  Oxborough 2009d [@pmed.1001619-Oxborough1]                                *An. gambiae* s.s. (Kisumu, lab strain)                   CTN deltamethrin 25 mg/m^2^ (on nylon nets)           No              Low                              Not stated                              Not stated           Not stated   Y   Y   Y

BF, blood fed; MM, mosquito mortality; NPT, not passed through net; RR, homozygous for the *kdr* allele; RS, heterozygous for the *kdr* allele.

For the risk of bias assessment, 16 comparisons reported comparability of ITN and UTN mosquito groups, whilst comparability was unclear in four comparisons ([Table S7](#pmed.1001619.s030){ref-type="supplementary-material"}). It was unclear in all studies whether observers were blinded. No comparison reported incomplete outcome data. Sixteen comparisons reported raw data for ITN and UTN groups, the remaining four did not.

### Experimental hut field trials {#s4b3}

The 24 included hut studies made 56 comparisons ([Table 9](#pmed-1001619-t009){ref-type="table"}). 20 comparisons used field sites in Côte D\'Ivoire, 14 in Tanzania, 11 in Benin, six in Burkina Faso, and five in Cameroon. Most comparisons (41 of 56) were of *An. gambiae* mosquitoes, 12 were of *An. arabiensis*, and three were of *An. funestus*. Two comparisons used laboratory-reared strains (Kisumu). Based on the reported WHO bioassay percent mortalities and *kdr* frequencies, 26 comparisons were carried out with mosquitoes with low resistance, 21 comparisons used highly resistant mosquitoes, and resistance was moderate for nine comparisons. Two comparisons measured metabolic resistance.

10.1371/journal.pmed.1001619.t009

###### Study characteristics of the included experimental hut trials.

![](pmed.1001619.t009){#pmed-1001619-t009-9}

  Study                                                               Study Location                 Study Start Date   Duration (Nights)               Mosquito Species (Strain/Origin)                         Intervention (All versus UTN)             Net Washed   Resistance Status                                         Resistance Testing                                                            Measured Outcomes                                                  
  ----------------------------------------------------- ------------------------------------------- ------------------ ------------------- ---------------------------------------------------------- --------------------------------------------------- ------------ ------------------- ------------------------------------------------------------------------------------------------ ---------------------------------------------------------- --------------- --- --- --- ---
  Asidi 2005a [@pmed.1001619-Asidi1]                     Yaokoffikro field station, Côte d\'Ivoire    15 August 2002           33                              *An. gambiae* s.s.                              CTN lambda-cyalothrin 18 mg/m^2^                No             High                                                        NS                                                          \>90%[a](#nt107){ref-type="table-fn"}                  NS         Y   Y   Y   Y
  Asidi 2005b [@pmed.1001619-Asidi1]                     Yaokoffikro field station, Côte d\'Ivoire    15 August 2002           33                              *An. gambiae* s.s.                              CTN lambda-cyalothrin 18 mg/m^2^               Yes             High                                                        NS                                                          \>90%[a](#nt107){ref-type="table-fn"}                  NS         Y   Y   Y   Y
  Chandre 2000 (Kisumu)a [@pmed.1001619-Chandre1]        Yaokoffikro field station, Côte d\'Ivoire          NS                 NS                   *An. gambiae* s.s. (Kisumu, lab strain)                       CTN deltamethrin 25 mg/m^2^                  No              Low                                             98.6% (permethrin 0.25%)                                                                 NS                                   NS         Y   Y   N   Y
  Chandre 2000 (Kisumu)b [@pmed.1001619-Chandre1]        Yaokoffikro field station, Côte d\'Ivoire          NS                 NS                   *An. gambiae* s.s. (Kisumu, lab strain)                       CTN permethrin 500 mg/m^2^                   No              Low                                             98.6% (permethrin 0.25%)                                                                 NS                                   NS         Y   Y   N   Y
  Chandre 2000 (YFO)a [@pmed.1001619-Chandre1]           Yaokoffikro field station, Côte d\'Ivoire          NS                 NS              *An. gambiae* s.s. (Yaokoffikro, wild population)                  CTN deltamethrin 25 mg/m^2^                  No             High                                                        NS                                                                          94.40%                                 NS         Y   Y   N   Y
  Chandre 2000 (YFO)b [@pmed.1001619-Chandre1]           Yaokoffikro field station, Côte d\'Ivoire          NS                 NS              *An. gambiae* s.s. (Yaokoffikro, wild population)                  CTN permethrin 500 mg/m^2^                   No             High                                                        NS                                                                          94.40%                                 NS         Y   Y   N   Y
  Corbel 2004a [@pmed.1001619-Corbel1]                      CREC field station, Cotonou, Benin              NS                 NS                         *An. gambiae* s.s. (M form)                             CTN permethrin 500 mg/m^2^                   No           Moderate                                                      NS                                                                          78.80%                                 NS         Y   Y   Y   Y
  Corbel 2004b [@pmed.1001619-Corbel1]                      CREC field station, Cotonou, Benin              NS                 NS                         *An. gambiae* s.s. (M form)                             CTN permethrin 250 mg/m^2^                   No           Moderate                                                      NS                                                                          63.40%                                 NS         Y   Y   Y   Y
  Corbel 2010 (Benin)a [@pmed.1001619-Corbel2]                       Malanville, Benin                      NS                 NS                         *An. gambiae* s.s. (S form)                                  LLIN PermaNet 2.0                       No              Low                                             85% (deltamethrin 0.05%)                                                                16%                                   NS         Y   Y   Y   Y
  Corbel 2010 (Benin)b [@pmed.1001619-Corbel2]                       Malanville, Benin                      NS                 NS                         *An. gambiae* s.s. (S form)                                  LLIN PermaNet 2.0                      Yes              Low                                             85% (deltamethrin 0.05%)                                                                16%                                   NS         Y   Y   Y   Y
  Corbel 2010 (Benin)c [@pmed.1001619-Corbel2]                       Malanville, Benin                      NS                 NS                         *An. gambiae* s.s. (S form)                                  LLIN PermaNet 3.0                       No              low                                             85% (deltamethrin 0.05%)                                                                16%                                   NS         Y   Y   Y   Y
  Corbel 2010 (Benin)d [@pmed.1001619-Corbel2]                       Malanville, Benin                      NS                 NS                         *An. gambiae* s.s. (S form)                                  LLIN PermaNet 3.0                      Yes              Low                                             85% (deltamethrin 0.05%)                                                                16%                                   NS         Y   Y   Y   Y
  Corbel 2010 (Benin)e [@pmed.1001619-Corbel2]                       Malanville, Benin                      NS                 NS                         *An. gambiae* s.s. (S form)                             CTN deltamethrin 25 mg/m^2^                 Yes              Low                                             85% (deltamethrin 0.05%)                                                                16%                                   NS         Y   Y   Y   Y
  Corbel 2010 (BFaso)a [@pmed.1001619-Corbel2]                  Valleé du Kou, Burkina Faso                 NS                 NS                  *An. gambiae* s.s. (15% M form/85% S form)                          LLIN PermaNet 2.0                       No             High                                             23% (deltamethrin 0.05%)                                                               \>80%                                  NS         Y   Y   Y   Y
  Corbel 2010 (BFaso)b [@pmed.1001619-Corbel2]                  Valleé du Kou, Burkina Faso                 NS                 NS                  *An. gambiae* s.s. (15% M form/85% S form)                          LLIN PermaNet 2.0                      Yes             High                                             23% (deltamethrin 0.05%)                                                               \>80%                                  NS         Y   Y   Y   Y
  Corbel 2010 (BFaso)c [@pmed.1001619-Corbel2]                  Valleé du Kou, Burkina Faso                 NS                 NS                  *An. gambiae* s.s. (15% M form/85% S form)                          LLIN PermaNet 3.0                       No             High                                             23% (deltamethrin 0.05%)                                                               \>80%                                  NS         Y   Y   Y   Y
  Corbel 2010 (BFaso)d [@pmed.1001619-Corbel2]                  Valleé du Kou, Burkina Faso                 NS                 NS                  *An. gambiae* s.s. (15% M form/85% S form)                          LLIN PermaNet 3.0                      Yes             High                                             23% (deltamethrin 0.05%)                                                               \>80%                                  NS         Y   Y   Y   Y
  Corbel 2010 (BFaso)e [@pmed.1001619-Corbel2]                  Valleé du Kou, Burkina Faso                 NS                 NS                 *A An. gambiae* s.s. (15% M form/85% S form)                    CTN deltamethrin 25 mg/m^2^                 Yes             High                                             23% (deltamethrin 0.05%)                                                               \>80%                                  NS         Y   Y   Y   Y
  Corbel 2010 (Cameroon)a [@pmed.1001619-Corbel1]                     Pitoa, Cameroon                       NS                 NS           *An. arabiensis* (95%), *An. gambiae* s.s. (5%) (S form)                   LLIN PermaNet 2.0                       No           Moderate                                           70% (deltamethrin 0.05%)                                                                \<5%                                  NS         Y   Y   Y   Y
  Corbel 2010 (Cameroon)b [@pmed.1001619-Corbel2]                     Pitoa, Cameroon                       NS                 NS           *An. arabiensis* (95%), *An. gambiae* s.s. (5%) (S form)                   LLIN PermaNet 2.0                      Yes           Moderate                                           70% (deltamethrin 0.05%)                                                                \<5%                                  NS         Y   Y   Y   Y
  Corbel 2010 (Cameroon)c [@pmed.1001619-Corbel2]                     Pitoa, Cameroon                       NS                 NS           *An. arabiensis* (95%), *An. gambiae* s.s. (5%) (S form)                   LLIN PermaNet 3.0                       No           Moderate                                           70% (deltamethrin 0.05%)                                                                \<5%                                  NS         Y   Y   Y   Y
  Corbel 2010 (Cameroon)d [@pmed.1001619-Corbel2]                     Pitoa, Cameroon                       NS                 NS           *An. arabiensis* (95%), *An. gambiae* s.s. (5%) (S form)                   LLIN PermaNet 3.0                      Yes           Moderate                                           70% (deltamethrin 0.05%)                                                                \<5%                                  NS         Y   Y   Y   Y
  Corbel 2010 (Cameroon)e [@pmed.1001619-Corbel2]                     Pitoa, Cameroon                       NS                 NS           *An. arabiensis* (95%), *An. gambiae* s.s. (5%) (S form)              CTN deltamethrin 25 mg/m^2^                 Yes           Moderate                                           70% (deltamethrin 0.05%)                                                                \<5%                                  NS         Y   Y   Y   Y
  Darriet 1998a [@pmed.1001619-Darriet2]                 Yaokoffikro field station, Côte d\'Ivoire          NS                 NS                              *An. gambiae* s.s.                                 CTN deltamethrin 25 mg/m^2^                  No           Moderate                                          67.0% (deltamethrin 0.25%)                                                                NS                                   NS         Y   Y   Y   Y
  Darriet 1998b [@pmed.1001619-Darriet2]                 Yaokoffikro field station, Côte d\'Ivoire          NS                 NS                              *An. gambiae* s.s.                                 CTN permethrin 500 mg/m^2^                   No             High                                             15.9% (permethrin 0.25%)                                                                 NS                                   NS         Y   Y   Y   Y
  Darriet 2000 [@pmed.1001619-Darriet3]                        M\'bé, Bouaké, Côte d\'Ivoire                NS                 NS                              *An. gambiae* s.s.                                 CTN deltamethrin 25 mg/m^2^                  No              Low                                            96.9% (deltamethrin 0.05%)                                                                NS                                   NS         Y   Y   Y   Y
  Fanello 1999a [@pmed.1001619-Fanello1]                          Bouaké, Côte d\'Ivoire                    NS                 NS                              *An. gambiae* s.s.                              CTN alpha-cypermethrin 20 mg/m^2^               No             High                                                        NS                                                                           90%                                   NS         Y   Y   N   Y
  Fanello 1999b [@pmed.1001619-Fanello1]                          Bouaké, Côte d\'Ivoire                    NS                 NS                              *An. gambiae* s.s.                                 CTN etofenprox 200 mg/m^2^                   No             High                                                        NS                                                                           90%                                   NS         Y   Y   N   Y
  Koudou 2011a [@pmed.1001619-Koudou1]                   Yaokoffikro field station, Côte d\'Ivoire      April 2009             84                              *An. gambiae* s.s.                                      LLIN PermaNet 3.0                       No             High                                            10.6% (deltamethrin 0.05%)                                                                NS                                   NS         Y   N   Y   Y
  Koudou 2011b [@pmed.1001619-Koudou1]                   Yaokoffikro field station, Côte d\'Ivoire      April 2009             84                              *An. gambiae* s.s.                                      LLIN PermaNet 2.0                       No             High                                            10.6% (deltamethrin 0.05%)                                                                NS                                   NS         Y   N   Y   Y
  Koudou 2011c [@pmed.1001619-Koudou1]                   Yaokoffikro field station, Côte d\'Ivoire      April 2009             84                              *An. gambiae* s.s.                                      LLIN PermaNet 3.0                      Yes             High                                            10.6% (deltamethrin 0.05%)                                                                NS                                   NS         Y   N   Y   Y
  Koudou 2011d [@pmed.1001619-Koudou1]                   Yaokoffikro field station, Côte d\'Ivoire      April 2009             84                              *An. gambiae* s.s.                                      LLIN PermaNet 2.0                      Yes             High                                            10.6% (deltamethrin 0.05%)                                                                NS                                   NS         Y   N   Y   Y
  Koudou 2011e [@pmed.1001619-Koudou1]                   Yaokoffikro field station, Côte d\'Ivoire      April 2009             84                              *An. gambiae* s.s.                                 CTN deltamethrin 25 mg/m^2^                 Yes             High                                            10.6% (deltamethrin 0.05%)                                                                NS                                   NS         Y   N   Y   Y
  Malima 2008 (funestus)a [@pmed.1001619-Malima1]                 Bouaké, Côte d\'Ivoire                    NS                 NS                                *An. funestus*                                           LLIN Olyset                          No              Low                                            100% (deltamethrin 0.05%)                                                                 NS                                   NS         Y   Y   Y   Y
  Malima 2008 (funestus)b [@pmed.1001619-Malima1]                 Bouaké, Côte d\'Ivoire                    NS                 NS                                *An. funestus*                                CTN alpha-cypermethrin 20 mg/m^2^               No              Low                                100% (deltamethrin 0.05%), 100% (permethrin 0.75%)                                                    NS                                   NS         Y   Y   Y   Y
  Malima 2008 (gambiae)a [@pmed.1001619-Malima1]                  Bouaké, Côte d\'Ivoire                    NS                 NS                              *An. gambiae* s.s.                                         LLIN Olyset                          No              Low                                100% (deltamethrin 0.05%), 100% (permethrin 0.75%)                                                    NS                                   NS         Y   Y   Y   Y
  Malima 2008 (gambiae)b [@pmed.1001619-Malima1]                  Bouaké, Côte d\'Ivoire                    NS                 NS                              *An. gambiae* s.s.                              CTN alpha-cypermethrin 20 mg/m^2^               No              Low                                100% (deltamethrin 0.05%), 100% (permethrin 0.75%)                                                    NS                                   NS         Y   Y   Y   Y
  Malima 2009 (funestus) [@pmed.1001619-Malima1]                     Muheza, Tanzania                       NS                 NS                                *An. funestus*                                   CTN deltamethrin 25 mg/m^2^                  No              Low                                            100% (deltamethrin 0.05%)                                                                 NS                                   NS         Y   Y   Y   N
  Malima 2009 (gambiae) [@pmed.1001619-Malima2]                      Muheza, Tanzania                       NS                 NS                              *An. gambiae* s.s.                                 CTN deltamethrin 25 mg/m^2^                  No              Low                                            100% (deltamethrin 0.05%)                                                                 NS                                   NS         Y   Y   Y   N
  N\'Guessan 2007 (Cotonou) [@pmed.1001619-NGuessan1]                  Ladji, Benin                         NS                 NS                              *An. gambiae* s.s.                              CTN lambda-cyalothrin 18 mg/m^2^                No             High                                                        NS                                                               83% lambda-cyalothin (0.05%)                 P450 activity   Y   Y   Y   Y
  N\'Guessan 2007 (M.ville) [@pmed.1001619-NGuessan1]                Malanville, Benin                      NS                 NS                              *An. gambiae* s.s.                              CTN lambda-cyalothrin 18 mg/m^2^                No              Low                                                        NS                                                                            6%                              P450 activity   Y   Y   Y   Y
  Ngufor 2011 (6 holes) [@pmed.1001619-Ngufor1]                        Akron, Benin                         NS                 NS                              *An. gambiae* s.s.                      LLIN deltamethrin 55 mg/m^2^, 6 holes in the net        No             High                                                        NS                                                                          \>80%                                  NS         Y   Y   Y   Y
  Ngufor 2011 (80 holes) [@pmed.1001619-Ngufor1]                       Akron, Benin                         NS                 NS                              *An. gambiae* s.s.                      LLIN deltamethrin 55 mg/m^2^, 80 holes in the net       No             High                                                        NS                                                                          \>80%                                  NS         Y   Y   Y   Y
  Okumu 2013 (dry season)a [@pmed.1001619-Okumu2]                Ulanga District, Tanzania                  NS                 NS                               *An. arabiensis*                                          LLIN Olyset                          No              Low                 100% (DDT), 95.5% (deltamethrin), 95.2% (permethrin), 90.2% (lambda-cyhalothrin)                                     NS                                   NS         Y   Y   Y   Y
  Okumu 2013 (dry season)b [@pmed.1001619-Okumu2]                Ulanga District, Tanzania                  NS                 NS                               *An. arabiensis*                                       LLIN PermaNet 2.0                       No              Low                 100% (DDT), 95.5% (deltamethrin), 95.2% (permethrin), 90.2% (lambda-cyhalothrin)                                     NS                                   NS         Y   Y   Y   Y
  Okumu 2013 (dry season)c [@pmed.1001619-Okumu2]                Ulanga District, Tanzania                  NS                 NS                               *An. arabiensis*                                        LLIN Icon Life                         No              Low                 100% (DDT), 95.5% (deltamethrin), 95.2% (permethrin), 90.2% (lambda-cyhalothrin)                                     NS                                   NS         Y   Y   Y   Y
  Okumu 2013 (wet season)a[@pmed.1001619-Okumu2]                 Ulanga District, Tanzania                  NS                 NS                               *An. arabiensis*                                          LLIN Olyset                          No              Low                 100% (DDT), 95.5% (deltamethrin), 95.2% (permethrin), 90.2% (lambda-cyhalothrin)                                     NS                                   NS         Y   Y   Y   Y
  Okumu 2013 (wet season)b [@pmed.1001619-Okumu2]                Ulanga District, Tanzania                  NS                 NS                               *An. arabiensis*                                       LLIN PermaNet 2.0                       No              Low                 100% (DDT), 95.5% (deltamethrin), 95.2% (permethrin), 90.2% (lambda-cyhalothrin)                                     NS                                   NS         Y   Y   Y   Y
  Okumu 2013 (wet season)c [@pmed.1001619-Okumu2]                Ulanga District, Tanzania                  NS                 NS                               *An. arabiensis*                                        LLIN Icon Life                         No              Low                 100% (DDT), 95.5% (deltamethrin), 95.2% (permethrin), 90.2% (lambda-cyhalothrin)                                     NS                                   NS         Y   Y   Y   Y
  Oxborough 2013 [@pmed.1001619-Oxborough2]                    KCMUC field station, Tanzania                NS                 NS                               *An. arabiensis*                               CTN alpha-cypermethrin 25 mg/m^2^               No           Moderate        58% (lambda-cyhalothrin 0.05%), 76% (permethrin 0.75%), 100% (DDT 4%), 100% (fenitrothrion 1%)   0% (L1014F), 0% (L1014S)[b](#nt108){ref-type="table-fn"}        NS         Y   Y   Y   Y
  Tungu 2010a [@pmed.1001619-Tungu1]                                 Muheza, Tanzania                       NS                 NS                              *An. gambiae* s.s.                                      LLIN PermaNet 2.0                       No              Low                                            100% (deltamethrin 0.05%)                                                                 NS                                   NS         Y   Y   Y   Y
  Tungu 2010b [@pmed.1001619-Tungu1]                                 Muheza, Tanzania                       NS                 NS                              *An. gambiae* s.s.                                      LLIN PermaNet 2.0                      Yes              Low                                            100% (deltamethrin 0.05%)                                                                 NS                                   NS         Y   Y   Y   Y
  Tungu 2010c [@pmed.1001619-Tungu1]                                 Muheza, Tanzania                       NS                 NS                              *An. gambiae* s.s.                                      LLIN PermaNet 3.0                       No              Low                                            100% (deltamethrin 0.05%)                                                                 NS                                   NS         Y   Y   Y   Y
  Tungu 2010d [@pmed.1001619-Tungu1]                                 Muheza, Tanzania                       NS                 NS                              *An. gambiae* s.s.                                      LLIN PermaNet 3.0                      Yes              Low                                            100% (deltamethrin 0.05%)                                                                 NS                                   NS         Y   Y   Y   Y
  Tungu 2010e [@pmed.1001619-Tungu1]                                 Muheza, Tanzania                       NS                 NS                              *An. gambiae* s.s.                                 CTN deltamethrin 25 mg/m^2^                 Yes              Low                                            100% (deltamethrin 0.05%)                                                                 NS                                   NS         Y   Y   Y   Y
  Djenontin 2010 [@pmed.1001619-Djenontin1]                     Valleé du Kou, Burkina Faso                 NS                 NS                         *An. gambiae* s.s. (M form)                                  LLIN PermaNet 2.0                       No             High                                                        NS                                                                           92%                                   NS         Y   Y   Y   Y

In mosquitoes from control huts (mosquitoes from the test huts were not screened).

Oxborough et al. [@pmed.1001619-Oxborough2] was the only study that tested for L104F and for L104S, but found no mutations for either.

BF, blood fed; BFaso, Burkina Faso; CREC, Entomological Research Centre of Cotonou; D, deterrence; IE, induced exophily; KCMUC, Kilimanjaro Christian Medical University College; M.ville, Malanville; MM, mosquito mortality; NS, not stated; YFO, Yaokoffikro.

For the risk of bias assessment, no comparisons reported comparability of ITN and UTN mosquito groups or blinded collectors of mosquitoes or the sleepers ([Table S8](#pmed.1001619.s031){ref-type="supplementary-material"}). Forty-eight of the 56 comparisons reported raw data for ITN and UTN groups. It was unclear in 16 comparisons as to whether nets were randomly allocated to huts at the start of the study. Overall, 41 comparisons rotated ITNs, eight did not, and seven did not report rotation. Fifty comparisons rotated sleepers, whilst it was unclear as to whether the remaining comparisons rotated the sleepers between huts.

[Table 10](#pmed-1001619-t010){ref-type="table"} displays the rigor of implementation assessment of each hut trial in terms of particular study design characteristics. Standardisation across studies both in terms of the experimental design and reporting was not consistent. Of the 16 comparisons that compared a washed net, 12 washed the net in accordance with the WHO protocol, one did not wash the net using WHO procedures, and it was unclear whether the remaining three had followed WHO procedures. Seven of the 56 comparisons cleaned the huts before the study, whereas 25 comparisons cleaned the huts after each rotation; the remaining comparisons were unclear regarding when the huts were cleaned. Overall, 38 of the 56 comparisons tested the ITNs before the study, 32 comparisons tested the ITNs on completion of the study, and 22 comparisons tested the nets chemically; the remaining comparisons did not test the nets. Outcomes were not measured on male mosquitoes in 30 of the 56 comparisons, but were measured in the remaining 26 comparisons.

10.1371/journal.pmed.1001619.t010

###### Assessment of "rigor" for experimental hut trials.

![](pmed.1001619.t010){#pmed-1001619-t010-10}

  Study                                                  Wash Procedure[a](#nt110){ref-type="table-fn"}   Huts Cleaned[b](#nt111){ref-type="table-fn"}   ITNs Tested   Male Mosquitoes Excluded from Study   Resistance Testing of Mosquitoes[f](#nt115){ref-type="table-fn"}                                
  ----------------------------------------------------- ------------------------------------------------ ---------------------------------------------- ------------- ------------------------------------- ------------------------------------------------------------------ ----- ----- ----- ----- ----- -----
  Asidi 2005a [@pmed.1001619-Asidi1]                                          n/a                                             Yes                          Unclear                     No                                                   No                                  No    Yes   No    Yes   No    No
  Asidi 2005b [@pmed.1001619-Asidi1]                                           No                                             Yes                          Unclear                     No                                                   No                                  No    Yes   No    Yes   No    No
  Chandre 2000 (Kisumu)a [@pmed.1001619-Chandre1]                             n/a                                           Unclear                        Unclear                     Yes                                                  No                                  No    Yes   Yes   No    No    No
  Chandre 2000 (Kisumu)b [@pmed.1001619-Chandre1]                             n/a                                           Unclear                        Unclear                     Yes                                                  No                                  No    Yes   Yes   No    No    No
  Chandre 2000 (YFO)a [@pmed.1001619-Chandre1]                                n/a                                           Unclear                        Unclear                     Yes                                                  No                                  No    Yes   No    Yes   No    No
  Chandre 2000 (YFO)b [@pmed.1001619-Chandre1]                                n/a                                           Unclear                        Unclear                     Yes                                                  No                                  No    Yes   No    Yes   No    No
  Corbel 2004a [@pmed.1001619-Corbel1]                                        n/a                                           Unclear                        Unclear                     No                                                   No                                  No    Yes   No    Yes   Yes   No
  Corbel 2004b [@pmed.1001619-Corbel1]                                        n/a                                           Unclear                        Unclear                     No                                                   No                                  No    Yes   No    Yes   Yes   No
  Corbel 2010 (Benin)a [@pmed.1001619-Corbel2]                                n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Benin)b [@pmed.1001619-Corbel2]                                Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Benin)c [@pmed.1001619-Corbel2]                                n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Benin)d [@pmed.1001619-Corbel2]                                Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Benin)e [@pmed.1001619-Corbel2]                                Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (BFaso)a [@pmed.1001619-Corbel2]                                n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (BFaso)b [@pmed.1001619-Corbel2]                                Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (BFaso)c [@pmed.1001619-Corbel2]                                n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (BFaso)d [@pmed.1001619-Corbel2]                                Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (BFaso)e [@pmed.1001619-Corbel2]                                Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Cameroon)a [@pmed.1001619-Corbel2]                             n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Cameroon)b [@pmed.1001619-Corbel2]                             Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Cameroon)c [@pmed.1001619-Corbel2]                             n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Cameroon)d [@pmed.1001619-Corbel2]                             Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Corbel 2010 (Cameroon)e [@pmed.1001619-Corbel2]                             Yes                                           Unclear                        Unclear                     Yes                                                 Yes                                  Yes   No    Yes   Yes   No    No
  Darriet 1998a [@pmed.1001619-Darriet2]                                      n/a                                           Unclear                          Yes                       No                                                  Yes                                  No    No    Yes   No    n/a   No
  Darriet 1998b [@pmed.1001619-Darriet2]                                      n/a                                           Unclear                          Yes                       No                                                  Yes                                  No    No    Yes   No    n/a   No
  Darriet 2000 [@pmed.1001619-Darriet3]                                       n/a                                           Unclear                        Unclear                     No                                                   No                                  No    Yes   Yes   No    n/a   No
  Fanello 1999a [@pmed.1001619-Fanello1]                                      n/a                                           Unclear                        Unclear                     No                                                   No                                  Yes   No    No    Yes   Yes   No
  Fanello 1999b [@pmed.1001619-Fanello1]                                      n/a                                           Unclear                        Unclear                     No                                                   No                                  Yes   No    No    Yes   Yes   No
  Koudou 2011a [@pmed.1001619-Koudou1]                                        n/a                                             Yes                            Yes                       Yes                                                 Yes                                  No    Yes   Yes   No    n/a   No
  Koudou 2011b [@pmed.1001619-Koudou1]                                        n/a                                             Yes                            Yes                       Yes                                                 Yes                                  No    Yes   Yes   No    n/a   No
  Koudou 2011c [@pmed.1001619-Koudou1]                                        Yes                                             Yes                            Yes                       Yes                                                 Yes                                  No    Yes   Yes   No    n/a   No
  Koudou 2011d [@pmed.1001619-Koudou1]                                        Yes                                             Yes                            Yes                       Yes                                                 Yes                                  No    Yes   Yes   No    n/a   No
  Koudou 2011e [@pmed.1001619-Tungu1]                                         Yes                                             Yes                            Yes                       Yes                                                 Yes                                  No    Yes   Yes   No    n/a   No
  Malima 2008 (funestus)a [@pmed.1001619-Malima1]                             n/a                                           Unclear                          Yes                       Yes                                                  No                                  No    Yes   Yes   No    n/a   No
  Malima 2008 (funestus)b [@pmed.1001619-Malima1]                             n/a                                           Unclear                          Yes                       Yes                                                  No                                  No    Yes   Yes   No    n/a   No
  Malima 2008 (gambiae)a [@pmed.1001619-Malima1]                              n/a                                           Unclear                          Yes                       Yes                                                  No                                  No    Yes   Yes   No    n/a   No
  Malima 2008 (gambiae)b [@pmed.1001619-Malima1]                              n/a                                           Unclear                          Yes                       Yes                                                  No                                  No    Yes   Yes   No    n/a   No
  Malima 2009 (funestus) [@pmed.1001619-Malima2]                              n/a                                           Unclear                          Yes                       Yes                                                 Yes                                  No    Yes   Yes   No    n/a   No
  Malima 2009 (gambiae) [@pmed.1001619-Malima2]                               n/a                                           Unclear                          Yes                       Yes                                                 Yes                                  No    Yes   Yes   No    n/a   No
  N\'Guessan 2007 (Cotonou) [@pmed.1001619-NGuessan1]                         n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  No    Yes   Yes   Yes   Yes   Yes
  N\'Guessan 2007 (M.ville) [@pmed.1001619-NGuessan1]                         n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  No    Yes   Yes   Yes   Yes   Yes
  Ngufor 2011 (6 holes) [@pmed.1001619-Ngufor1]                               n/a                                           Unclear                        Unclear                     No                                                   No                                  No    Yes   No    Yes   Yes   No
  Ngufor 2011 (80 holes) [@pmed.1001619-Ngufor1]                              n/a                                           Unclear                        Unclear                     No                                                   No                                  No    Yes   No    Yes   Yes   No
  Okumu 2013 (dry season)a [@pmed.1001619-Okumu2]                             n/a                                           Unclear                          Yes                       No                                                   No                                  No    No    Yes   No    n/a   No
  Okumu 2013 (dry season)b [@pmed.1001619-Okumu2]                             n/a                                           Unclear                          Yes                       No                                                   No                                  No    No    Yes   No    n/a   No
  Okumu 2013 (dry season)c [@pmed.1001619-Okumu2]                             n/a                                           Unclear                          Yes                       No                                                   No                                  No    No    Yes   No    n/a   No
  Okumu 2013 (wet season)a [@pmed.1001619-Okumu2]                             n/a                                           Unclear                          Yes                       No                                                   No                                  No    No    Yes   No    n/a   No
  Okumu 2013 (wet season)b [@pmed.1001619-Okumu2]                             n/a                                           Unclear                          Yes                       No                                                   No                                  No    No    Yes   No    n/a   No
  Okumu 2013 (wet season)c [@pmed.1001619-Okumu2]                             n/a                                           Unclear                          Yes                       No                                                   No                                  No    No    Yes   No    n/a   No
  Oxborough 2013 [@pmed.1001619-Oxborough2]                                   n/a                                           Unclear                          Yes                       No                                                   No                                  No    No    Yes   Yes   Yes   No
  Tungu 2010a [@pmed.1001619-Tungu1]                                          n/a                                           Unclear                          Yes                       Yes                                                 Yes                                  Yes   Yes   Yes   No    n/a   No
  Tungu 2010b [@pmed.1001619-Tungu1]                                        Unclear                                         Unclear                          Yes                       Yes                                                 Yes                                  Yes   Yes   Yes   No    n/a   No
  Tungu 2010c [@pmed.1001619-Tungu1]                                          n/a                                           Unclear                          Yes                       Yes                                                 Yes                                  Yes   Yes   Yes   No    n/a   No
  Tungu 2010d [@pmed.1001619-Tungu1]                                        Unclear                                         Unclear                          Yes                       Yes                                                 Yes                                  Yes   Yes   Yes   No    n/a   No
  Tungu 2010e [@pmed.1001619-Tungu1]                                        Unclear                                         Unclear                          Yes                       Yes                                                 Yes                                  Yes   Yes   Yes   No    n/a   No
  Djenontin 2010 [@pmed.1001619-Djenontin1]                                   n/a                                           Unclear                        Unclear                     Yes                                                 Yes                                  No    Yes   No    Yes   Yes   No

Nets washed in accordance with WHO standardised protocol [@pmed.1001619-Ranson3]. n/a indicates the net was unwashed.

Huts cleaned and ventilated before the start of the study and after each rotation of net to prevent cross-contamination of insecticide.

Bioassays using laboratory-reared mosquito populations conducted on ITNs before the study to ensure that impregnation of nets has been performed correctly.

Bioassays using laboratory-reared mosquito populations conducted on ITNs at the end of the study to measure the residual activity.

Chemical analysis of ITNs to ensure the correct dosage of insecticide is present.

Resistance status of mosquito populations assessed using bioassay to measure the level of phenotypic resistance, *kdr* genotyping to measure the frequency of the L1014F or L1014S mutation, and metabolic resistance testing, which can be carried out using synergists, biochemical enzyme analysis, or gene expression profiling.

n/a indicates *kdr* was not measured.

BFaso, Burkina Faso; M.ville, Malanville; n/a, not applicable; YFO, Yaokoffikro.

Characterisation of resistance was not consistent across studies. Seventeen comparisons measured phenotypic resistance using bioassays complemented with *kdr* genotyping in the mosquito populations under investigation. Bioassays on their own were used in 27 comparisons, whilst 11 comparisons were performed on mosquitoes for which only *kdr* genotyping was used. Characterisation of metabolic resistance was reported in just two studies, where the authors also measured phenotypic resistance and *kdr*. For those studies which screened for *kdr*, ten stated the number of mosquitoes that had been genotyped.

Relationship between Resistance and Entomological Outcomes {#s4c}
----------------------------------------------------------

### Cone tests {#s4c1}

Forty-seven cone test comparisons reported mosquito mortality (21 low, 20 moderate, and five high resistance and one unclear) ([Figure S1](#pmed.1001619.s001){ref-type="supplementary-material"}). Mortality was very low in the untreated net group, and the risk of mosquito mortality is much higher using ITNs as compared with UTNs regardless of resistance. The study-specific RDs showed huge variability within all three categories of resistance. The meta-analytic results showed that the difference in mortality risk using ITNs as compared with UTNs decreased as resistance increased. Nevertheless, mortality risk was significantly higher for ITNs compared to UTNs regardless of resistance: with low resistance, the difference in risk of mortality is 0.86 (95% CI 0.72 to 1.01; 4,626 mosquitoes, 21 comparisons; *I* ^2^ = 100%, 95% CI 100% to 100%); in the case of moderate resistance the difference in risk is 0.71 (95% CI 0.53 to 0.88; 5,760 mosquitoes, 20 comparisons; *I* ^2^ = 100%, 95% CI 100% to 100%); with high resistance, the difference in risk is 0.56 (95% CI 0.17 to 0.95; 784 mosquitoes, five comparisons; *I* ^2^ = 99%, 95% CI 99% to 100%). The test for subgroup differences did not demonstrate a difference in the RD between high, medium, and low resistance subgroups (*p* = 0.12, *I* ^2^ = 49%, 95% CI 23% to 66%). A further 12 comparisons (seven low resistance, five high) presented data that could not be combined in meta-analysis ([Table 11](#pmed-1001619-t011){ref-type="table"}).

10.1371/journal.pmed.1001619.t011

###### Results from cone tests comparing LLIN or CTN versus UTN for mosquito mortality and knock-down at 60 min.

![](pmed.1001619.t011){#pmed-1001619-t011-11}

  Study                                              Intervention (All versus UTN)     Net Washed              Mosquito Species (Strain)               Resistance Status   Mosquito Mortality   Knock-Down at 60 min                  
  ----------------------------------------------- ----------------------------------- ------------ -------------------------------------------------- ------------------- -------------------- ---------------------- ------ ---- --- ------
  Koudou 2011 (Kisumu)a [@pmed.1001619-Koudou1]            LLIN PermaNet 3.0               No                 *An. gambiae* s.s. (Kisumu)                     Low                  99                    0             0.99   98   0   0.98
  Koudou 2011 (Kisumu)b [@pmed.1001619-Koudou1]            LLIN PermaNet 3.0              Yes                 *An. gambiae* s.s. (Kisumu)                     Low                  99                    0             0.99   98   0   0.98
  Koudou 2011 (Kisumu)c [@pmed.1001619-Koudou1]            LLIN PermaNet 2.0               No                 *An. gambiae* s.s. (Kisumu)                     Low                 100                    0              1     99   0   0.99
  Koudou 2011 (Kisumu)d [@pmed.1001619-Koudou1]            LLIN PermaNet 2.0              Yes                 *An. gambiae* s.s. (Kisumu)                     Low                  99                    0             0.99   97   0   0.97
  Koudou 2011 (Kisumu)e [@pmed.1001619-Koudou1]       CTN deltamethrin 25 mg/m^2^         Yes                 *An. gambiae* s.s. (Kisumu)                     Low                  95                    0             0.95   95   0   0.95
  Malima 2008 (cone)a [@pmed.1001619-Malima1]                 LLIN Olyset                  No                 *An. gambiae* s.s. (Kisumu)                     Low                  99                    0             0.99   75   0   0.75
  Malima 2008 (cone)b [@pmed.1001619-Malima1]      CTN alpha-cypermethrin 20 mg/m^2^       No                 *An. gambiae* s.s. (Kisumu)                     Low                  84                    0             0.84   88   0   0.88
  Koudou 2011 (YFO)a [@pmed.1001619-Koudou1]               LLIN PermaNet 3.0               No       *An. gambiae* s.s. (Yaokoffikro wild population)         High                  48                    0             0.48   77   0   0.77
  Koudou 2011 (YFO)b [@pmed.1001619-Koudou1]               LLIN PermaNet 3.0              Yes       *An. gambiae* s.s. (Yaokoffikro wild population)         High                  95                    0             0.95   95   0   0.95
  Koudou 2011 (YFO)c [@pmed.1001619-Koudou1]               LLIN PermaNet 2.0               No       *An. gambiae* s.s. (Yaokoffikro wild population)         High                  42                    0             0.42   84   0   0.84
  Koudou 2011 (YFO)d [@pmed.1001619-Koudou1]               LLIN PermaNet 2.0              Yes       *An. gambiae* s.s. (Yaokoffikro wild population)         High                  82                    0             0.82   90   0   0.9
  Koudou 2011 (YFO)e [@pmed.1001619-Koudou1]          CTN deltamethrin 25 mg/m^2^         Yes       *An. gambiae* s.s. (Yaokoffikro wild population)         High                  8                     0             0.08   17   0   0.17

YFO, Yaokoffikro.

Nine comparisons reported percentage knock-down at 60 min (six low resistance, two high, one unclear; [Figure S2](#pmed.1001619.s002){ref-type="supplementary-material"}). In mosquitoes with low resistance, the risk of being knocked down is significantly higher using ITNs as compared with UTNs, but with high resistance, there is no difference between ITNs and UTNs. A significant difference is detected between the meta-analytic results for mosquitoes with low, unclear, and high resistance (*p*\<0.00001, *I* ^2^ = 98.8%, 95% CI 98.3% to 99.2%).

The majority of studies show that the risk of knock-down is higher using ITNs than using UTNs, regardless of resistance. In mosquitoes with low resistance, the difference in risk of knock-down is 0.87 (95% CI 0.69 to 1.05; 3,440 mosquitoes, 17 comparisons; *I* ^2^ = 100%, 95% CI 100% to 100%); with high resistance, the difference in risk is 0.09 (95% CI −0.03 to 0.21; 309 mosquitoes, two comparisons; *I* ^2^ = 87%, 95% CI 94% to 97%). There is high variability between the results from studies within the same resistance category, although all comparisons tend to favour ITNs. A further 12 comparisons (seven low resistance, five high) presented data that could not be combined in meta-analysis ([Table 11](#pmed-1001619-t011){ref-type="table"}).

Seven cone test comparisons reported time to 50% knock-down (four low resistance, three high), and two comparisons presented time to 95% knock-down (one low, one high). By visual inspection of [Table 5](#pmed-1001619-t005){ref-type="table"}, the knock-down times tend to be longer in studies of mosquitoes with high resistance than in studies of mosquitoes with low resistance. However, this comparison is made across trials and may be subject to confounding.

### Tunnel tests {#s4c2}

Fourteen tunnel test comparisons reported feeding (eight low resistance, two moderate, six high) ([Figure S3](#pmed.1001619.s003){ref-type="supplementary-material"}). The higher the resistance, the lower the effectiveness of ITNs (as compared with UTNs). A significant difference is detected between the meta-analytic results for mosquitoes with low, moderate, and high resistance (*p* = 0.001, *I* ^2^ = 85.1%, 95% CI 68.7% to 92.9%). A lower risk of blood feeding is apparent when using ITNs as compared with UTNs, regardless of resistance. For mosquitoes with low resistance, the difference in the risk of blood feeding is −0.66 (95% CI −0.77 to −0.55; 2,177 mosquitoes, eight comparisons; *I* ^2^ = 92%, 95% CI 87% to 95%); for mosquitoes with moderate resistance, the difference in risk is −0.53 (95% CI −0.63 to −0.42; 300 mosquitoes, two comparisons; *I* ^2^ = 0% 95% CI not estimable); and for mosquitoes with high resistance, the difference in risk is −0.27 (95% CI −0.45 to −0.09; 2,472 mosquitoes, six comparisons; *I* ^2^ = 97%, 95% CI 94% to 98%). There is high variability among the results from studies of mosquitoes with low resistance and also among those from studies of mosquitoes with high resistance, although most comparisons significantly favour ITNs. Four additional comparisons (low resistance) presented data that could not be combined in meta-analysis ([Table 6](#pmed-1001619-t006){ref-type="table"}).

Sixteen tunnel test comparisons reported mosquito mortality (eight low resistance, two moderate, six high) ([Figure S4](#pmed.1001619.s004){ref-type="supplementary-material"}). The risk of mortality is significantly higher using ITNs as compared with UTNs, regardless of resistance. The meta-analytic results showed that the difference in mortality risk using ITNs as compared with UTNs decreased as resistance increased. The test for subgroup differences showed significant variability between the meta-analytic results from low, moderate, and high resistance subgroups (*p* = 0.001, *I* ^2^ = 84.7%, 95% CI 67.9% to 92.7%). For mosquitoes with low resistance, the difference in risk is 0.74 (95% CI 0.61 to 0.87; 2,177 mosquitoes, eight comparisons; *I* ^2^ = 96%, 95% CI 94% to 97%); for mosquitoes with moderate resistance, the difference in risk is 0.50 (95% CI 0.40 to 0.60; 300 mosquitoes, two comparisons; *I* ^2^ = 11%, 95% CI not estimable); and for mosquitoes with high resistance, the difference in risk is 0.39 (95% CI 0.24 to 0.54; 2,472 mosquitoes, six comparisons; *I* ^2^ = 95%, 95% CI 94% to 98%). There is high variability among the results from studies of mosquitoes with low resistance and also among those from studies of mosquitoes with high resistance, yet almost all comparisons significantly favour ITNs. [Table 6](#pmed-1001619-t006){ref-type="table"} shows the results of additional comparisons (low resistance) that could not be combined in meta-analysis.

Six tunnel test comparisons reported whether mosquitoes could not pass through the net (four low resistance, two high) ([Figure S5](#pmed.1001619.s005){ref-type="supplementary-material"}). Results show that the higher the resistance, the lower the effectiveness of ITNs (as compared with UTNs). The observed trend could be caused by differences in characteristics (other than resistance) between the studies of low resistance mosquitoes and those of high resistance mosquitoes. A significant difference is detected between the meta-analytic results for low and high resistance mosquitoes (*p*\<0.00001, *I* ^2^ = 98.4%, 95% CI 97.1% to 99.1%).

The risk of not passing though the net is significantly higher when using ITNs than when using UTNs, regardless of mosquito resistance. In mosquitoes with low resistance, the difference in risk is 0.68 (95% CI 0.62 to 0.75; 1,140 mosquitoes, four comparisons; *I* ^2^ = 61%, 95% CI 0% to 87%), and in mosquitoes with high resistance, the difference in risk is 0.36 (95% CI 0.31 to 0.41; 1,309 mosquitoes, two comparisons; *I* ^2^ = 0%, 95% CI not estimable). There is variability among the results from studies of mosquitoes with low resistance, yet all comparisons significantly favour ITNs. Four additional comparisons (low resistance) presented data that could not be combined in meta-analysis ([Table 6](#pmed-1001619-t006){ref-type="table"}).

### Experimental hut trials {#s4c3}

Overall, 44 hut trial comparisons reported blood feeding (20 low resistance, nine moderate, 15 high) ([Figure 2](#pmed-1001619-g002){ref-type="fig"}). There is no clear relationship between resistance and the effectiveness of ITNs. A significant difference is not detected between the meta-analytic results for low, moderate, and high resistance groups (*p* = 0.84, *I* ^2^ = 0%, 95% CI 0% to 35%).

![Forest plot for experimental hut trials comparing LLIN or CTN versus UTN for blood feeding.\
BFaso, Burkina Faso; M-H, Mantel-Haenszel; M.ville, Malanville (Benin); YFO, Yaokoffikro, (Côte d\'Ivoire).](pmed.1001619.g002){#pmed-1001619-g002}

Blood feeding was reduced when using ITNs as compared with UTNs, regardless of resistance. In mosquitoes with low resistance, the difference in the risk of blood feeding is −0.24 (95% CI −0.34 to −0.14; 11,395 mosquitoes, 20 comparisons; *I* ^2^ = 97%, 95% CI 96% to 98%); in mosquitoes with moderate resistance, the difference in risk is −0.25 (95% CI −0.31 to −0.19; 2,578 mosquitoes, eight comparisons; *I* ^2^ = 46%, 95% CI 0% to 76%); and in mosquitoes with high resistance, the difference in risk is −0.28 (95% CI −0.37 to −0.19; 8,129 mosquitoes, 16 comparisons; *I* ^2^ = 94%, 95% CI 92% to 96%). There is particularly high variability among the results from studies of mosquitoes with low resistance and among those from studies of mosquitoes with high resistance, although most comparisons significantly favour ITNs. One comparison [@pmed.1001619-Ndiath1], with high resistance, reported 38% and 68% blood feeding (figures estimated from graph) in the ITN and UTN groups, respectively (RD = 0.3).

Fifty-three hut trial comparisons reported mosquito mortality (24 low resistance, eight moderate, 20 high) ([Figure 3](#pmed-1001619-g003){ref-type="fig"}). There is high heterogeneity across study-specific results with each category of resistance. In addition, one study [@pmed.1001619-Okumu2] appears to show no evidence of an effect of ITNs in low resistance mosquitoes. The authors also report on the bioassay, which shows 90%--100% susceptibility to insecticides. However, mortality risk was higher for ITNs compared to UTNs irrespective of the resistance category. In mosquitoes with low resistance, the difference in risk is 0.56 (95% CI 0.43 to 0.68; 67,610 mosquitoes, 24 comparisons; *I* ^2^ = 100%, 95% CI 100% to 100%); in mosquitoes with moderate resistance, the difference in risk is 0. 39 (95% CI 0.16 to 0.61; 2,578 mosquitoes, eight comparisons; *I* ^2^ = 98%, 95% CI 97% to 98%); and with high resistance, the difference in risk is 0.35 (95% CI 0.27 to 0.43; 10,417 mosquitoes, 21 comparisons; *I* ^2^ = 96%, 95% CI 95% to 97%). The meta-analytic results showed that the difference in mortality risk using ITNs as compared with UTNs modestly decreased as resistance increased, and the test for subgroup differences demonstrated a difference in the RD between high, medium, and low resistance subgroups (*p* = 0.03, *I* ^2^ = 72.0%, 95% CI 58.7% to 81.0%).

![Forest plot for experimental hut trials comparing LLIN or CTN versus UTN for mosquito mortality.\
BFaso, Burkina Faso; M-H, Mantel-Haenszel; M.ville, Malanville (Benin); YFO, Yaokoffikro, (Côte d\'Ivoire).](pmed.1001619.g003){#pmed-1001619-g003}

One comparison [@pmed.1001619-Ndiath1], with high resistance mosquitoes, reported 42% and 2% mortality (figures estimated from graph) in the ITN and UTN groups, respectively (RD = 0.4).

Forty-three trial hut comparisons reported results for induced exophily (18 low resistance, nine moderate, 16 high) ([Figure 4](#pmed-1001619-g004){ref-type="fig"}). There is no clear relationship between resistance and the effectiveness of ITNs in relation to this outcome. A significant difference is detected between the meta-analytic results for low, moderate, and high resistance (*p* = 0.0002, *I* ^2^ = 88.2%, 95% CI 81.6% to 92.3%).

![Forest plot for experimental hut trials comparing LLIN or CTN versus UTN for induced exophily.\
BFaso, Burkina Faso; M-H, Mantel-Haenszel; M.ville, Malanville (Benin); YFO, Yaokoffikro, (Côte d\'Ivoire).](pmed.1001619.g004){#pmed-1001619-g004}

Generally, the risk of exiting the hut is higher using ITNs than using UTNs, regardless of resistance. For mosquitoes with low resistance, the difference in risk is 0.09 (95% CI 0.04 to 0.15; 11,014 mosquitoes, 18 comparisons; *I* ^2^ = 92%, 95% CI 89% to 94%); for mosquitoes with moderate resistance, the difference in risk is 0.28 (95% CI 0.17 to 0.40; 2,578 mosquitoes, eight comparisons; *I* ^2^ = 85%, 95% CI 73% to 92%); and for mosquitoes with high resistance, the difference in risk is 0.26 (95% CI 0.19 to 0.33; 8,695 mosquitoes, 16 comparisons; *I* ^2^ = 90%, 95% CI 86% to 93%). There is substantive heterogeneity within and across resistance groups, but most comparisons significantly favour ITNs. One comparison [@pmed.1001619-Ndiath1], with high resistance mosquitoes, reported 80% and 20% induced exophily (figures estimated from graph) in the ITN and UTN groups, respectively (RD = 0.6).

Fifty-five comparisons reported on deterrence (21 low resistance, 13 moderate, 21 high) ([Table 12](#pmed-1001619-t012){ref-type="table"}). There is no clear relationship between resistance status and deterrence based on a visual inspection of the results.

10.1371/journal.pmed.1001619.t012

###### Results from experimental hut trials comparing LLIN or CTN versus UTN for deterrence.

![](pmed.1001619.t012){#pmed-1001619-t012-12}

  Study                                                       Intervention (All versus UTN)         Net Washed    Mosquito Species    Total Number in ITN Huts   Resistance Status   Total Number in UTN Huts   Deterrence (Percent)
  ----------------------------------------------------- ------------------------------------------ ------------ -------------------- -------------------------- ------------------- -------------------------- ----------------------
  Chandre 2000 (Kisumu)a [@pmed.1001619-Chandre1]              CTN deltamethrin 25 mg/m^2^              No       *An. gambiae* s.s.             107                     Low                    126                       15
  Chandre 2000 (Kisumu)b [@pmed.1001619-Chandre1]               CTN permethrin 500 mg/m^2^              No       *An. gambiae* s.s.             148                     Low                    126                      −17
  Darriet 2000 [@pmed.1001619-Darriet3]                        CTN deltamethrin 25 mg/m^2^              No       *An. gambiae* s.s.             553                     Low                   1,998                      72
  Malima 2008 (funestus)a [@pmed.1001619-Malima1]                      LLIN Olyset                      No         *An. funestus*               222                     Low                    315                       30
  Malima 2008 (funestus)b [@pmed.1001619-Malima1]           CTN alpha-cypermethrin 20 mg/m^2^           No         *An. funestus*               211                     Low                    315                       33
  Malima 2008 (gambiae)a [@pmed.1001619-Malima1]                       LLIN Olyset                      No       *An. gambiae* s.s.             177                     Low                    112                      −58
  Malima 2008 (gambiae)b [@pmed.1001619-Malima1]                CTN permethrin 500 mg/m^2^              No       *An. gambiae* s.s.              93                     Low                    112                       17
  Malima 2009 (funestus) [@pmed.1001619-Malima2]               CTN deltamethrin 25 mg/m^2^              No         *An. funestus*               327                     Low                    270                      −21
  Malima 2009 (gambiae) [@pmed.1001619-Malima2]                CTN deltamethrin 25 mg/m^2^              No       *An. gambiae* s.s.             740                     Low                    493                      −50
  N\'Guessan 2007 (M.ville) [@pmed.1001619-NGuessan1]        CTN lambda-cyalothrin 18 mg/m^2^           No       *An. gambiae* s.s.             267                     Low                    363                       26
  Tungu 2010a [@pmed.1001619-Tungu1]                                LLIN PermaNet 2.0                   No       *An. gambiae* s.s.             574                     Low                    723                       21
  Tungu 2010b [@pmed.1001619-Tungu1]                                LLIN PermaNet 2.0                  Yes       *An. gambiae* s.s.             586                     Low                    723                       19
  Tungu 2010c [@pmed.1001619-Tungu1]                                LLIN PermaNet 3.0                   No       *An. gambiae* s.s.             425                     Low                    723                       41
  Tungu 2010d [@pmed.1001619-Tungu1]                                LLIN PermaNet 3.0                  Yes       *An. gambiae* s.s.             558                     Low                    723                       23
  Tungu 2010e [@pmed.1001619-Tungu1]                           CTN deltamethrin 25 mg/m^2^             Yes       *An. gambiae* s.s.             560                     Low                    723                       23
  Okumu 2013 (dry season)a [@pmed.1001619-Okumu2]                      LLIN Olyset                      No        *An. arabiensis*             6,047                 Moderate                 4,596                     −32
  Okumu 2013 (dry season)b [@pmed.1001619-Okumu2]                   LLIN PermaNet 2.0                   No        *An. arabiensis*             4,420                 Moderate                 4,596                      4
  Okumu 2013 (dry season)c [@pmed.1001619-Okumu2]        LLIN Icon Life (deltamethrin 65 mg/m^2^)       No        *An. arabiensis*             6,492                 Moderate                 4,596                     −41
  Okumu 2013 (wet season)a [@pmed.1001619-Okumu2]                      LLIN Olyset                      No        *An. arabiensis*             9,789                 Moderate                 7,181                     −36
  Okumu 2013 (wet season)b [@pmed.1001619-Okumu2]                   LLIN PermaNet 2.0                   No        *An. arabiensis*             8,240                 Moderate                 7,181                     −15
  Okumu 2013 (wet season)c [@pmed.1001619-Okumu2]                     LLIN Icon Life                    No        *An. arabiensis*             11,279                Moderate                 7,181                     −57
  Corbel 2004a [@pmed.1001619-Corbel1]                          CTN permethrin 500 mg/m^2^              No       *An. gambiae* s.s.              60                  Moderate                  520                       88
  Corbel 2004b [@pmed.1001619-Corbel1]                          CTN permethrin 250 mg/m^2^              No       *An. gambiae* s.s.              56                  Moderate                  520                       89
  Corbel 2010 (Benin)a [@pmed.1001619-Corbel2]                      LLIN PermaNet 2.0                   No       *An. gambiae* s.s.             243                  Moderate                  285                       15
  Corbel 2010 (Benin)b [@pmed.1001619-Corbel2]                      LLIN PermaNet 2.0                  Yes       *An. gambiae* s.s.             195                  Moderate                  285                       32
  Corbel 2010 (Benin)c [@pmed.1001619-Corbel2]                      LLIN PermaNet 3.0                   No       *An. gambiae* s.s.             214                  Moderate                  285                       25
  Corbel 2010 (Benin)d [@pmed.1001619-Corbel2]                      LLIN PermaNet 3.0                  Yes       *An. gambiae* s.s.             210                  Moderate                  285                       26
  Corbel 2010 (Benin)e [@pmed.1001619-Corbel2]                 CTN deltamethrin 25 mg/m^2^             Yes       *An. gambiae* s.s.             297                  Moderate                  285                       −4
  Corbel 2010 (Cameroon)a [@pmed.1001619-Corbel2]                   LLIN PermaNet 2.0                   No       *An. gambiae* s.s.             105                  Moderate                  401                       74
  Corbel 2010 (Cameroon)b [@pmed.1001619-Corbel2]                   LLIN PermaNet 2.0                  Yes       *An. gambiae* s.s.             310                  Moderate                  401                       23
  Corbel 2010 (Cameroon)c [@pmed.1001619-Corbel2]                   LLIN PermaNet 3.0                   No       *An. gambiae* s.s.             146                  Moderate                  401                       64
  Corbel 2010 (Cameroon)d [@pmed.1001619-Corbel2]                   LLIN PermaNet 3.0                  Yes       *An. gambiae* s.s.             163                  Moderate                  401                       59
  Corbel 2010 (Cameroon)e [@pmed.1001619-Corbel2]              CTN deltamethrin 25 mg/m^2^             Yes       *An. gambiae* s.s.             565                  Moderate                  401                      −41
  Oxborough 2013 [@pmed.1001619-Oxborough2]                 CTN alpha-cypermethrin 25 mg/m^2^           No        *An. arabiensis*              110                  Moderate                  143                       23
  Asidi 2005a [@pmed.1001619-Asidi1]                         CTN lambda-cyalothrin 18 mg/m^2^           No       *An. gambiae* s.s.              34                    High                     83                       59
  Asidi 2005b [@pmed.1001619-Asidi1]                         CTN lambda-cyalothrin 18 mg/m^2^          Yes       *An. gambiae* s.s.              24                    High                     83                       71
  Chandre 2000 (YFO)a [@pmed.1001619-Chandre1]                 CTN deltamethrin 25 mg/m^2^              No       *An. gambiae* s.s.             198                    High                    247                       20
  Chandre 2000 (YFO)b [@pmed.1001619-Chandre1]                  CTN permethrin 500 mg/m^2^              No       *An. gambiae* s.s.             210                    High                    247                       15
  Corbel 2010 (BFaso)a [@pmed.1001619-Corbel2]                      LLIN PermaNet 2.0                   No       *An. gambiae* s.s.             329                    High                    908                       64
  Corbel 2010 (BFaso)b [@pmed.1001619-Corbel2]                      LLIN PermaNet 2.0                  Yes       *An. gambiae* s.s.             788                    High                    908                       13
  Corbel 2010 (BFaso)c [@pmed.1001619-Corbel2]                      LLIN PermaNet 3.0                   No       *An. gambiae* s.s.             463                    High                    908                       49
  Corbel 2010 (BFaso)d [@pmed.1001619-Corbel2]                      LLIN PermaNet 3.0                  Yes       *An. gambiae* s.s.             724                    High                    908                       20
  Corbel 2010 (BFaso)e [@pmed.1001619-Corbel2]                 CTN deltamethrin 25 mg/m^2^             Yes       *An. gambiae* s.s.            1,056                   High                    908                      −16
  Darriet 1998a [@pmed.1001619-Darriet2]                       CTN deltamethrin 25 mg/m^2^              No       *An. gambiae* s.s.             211                    High                    373                       43
  Darriet 1998b [@pmed.1001619-Darriet2]                        CTN permethrin 500 mg/m^2^              No       *An. gambiae* s.s.             307                    High                    373                       18
  Fanello 1999a [@pmed.1001619-Fanello1]                    CTN alpha-cypermethrin 20 mg/m^2^           No       *An. gambiae* s.s.             378                    High                    149                      −154
  Fanello 1999b [@pmed.1001619-Fanello1]                        CTN etofenprox 200 mg/m^2^              No       *An. gambiae* s.s.             140                    High                    149                       6
  Koudou 2011b [@pmed.1001619-Koudou1]                              LLIN PermaNet 2.0                   No       *An. gambiae* s.s.             317                    High                    796                       60
  Koudou 2011d [@pmed.1001619-Koudou1]                              LLIN PermaNet 2.0                  Yes       *An. gambiae* s.s.             281                    High                    796                       64
  Koudou 2011a [@pmed.1001619-Koudou1]                              LLIN PermaNet 3.0                   No       *An. gambiae* s.s.             303                    High                    796                       62
  Koudou 2011c [@pmed.1001619-Koudou1]                              LLIN PermaNet 3.0                  Yes       *An. gambiae* s.s.             313                    High                    796                       60
  Koudou 2011e [@pmed.1001619-Koudou1]                         CTN deltamethrin 25 mg/m^2^             Yes       *An. gambiae* s.s.             279                    High                    796                       64
  N\'Guessan 2007 (Cotonou) [@pmed.1001619-NGuessan1]        CTN lambda-cyalothrin 18 mg/m^2^           No       *An. gambiae* s.s.             386                    High                    689                       44
  Ngufor 2011 (6 holes) [@pmed.1001619-Ngufor1]           LLIN deltamethrin 55 mg/m^2^, 6 holes         No       *An. gambiae* s.s.              91                    High                     78                      −17
  Ngufor 2011 (80 holes) [@pmed.1001619-Ngufor1]          LLIN deltamethrin 55 mg/m^2^, 80 holes        No       *An. gambiae* s.s.             110                    High                    147                       25

BFaso, Burkina Faso; M.ville, Malanville; YFO, Yaokoffikro.

Results of Subgroup Analyses, Sensitivity Analyses, and Funnel Plots {#s4d}
--------------------------------------------------------------------

Considerable heterogeneity was found across all studies, therefore sources of heterogeneity were explored using subgroup analyses. We carried out subgroup analyses by net type, insecticide used, the concentration of insecticide, and whether nets were washed or not. Because of the wide variation between studies in relation to these factors, these plots were numerous. We carried out analyses grouping in different ways, but these analyses did not provide any explanation of the heterogeneity between studies. The funnel plots do not resemble symmetric funnels; this may be because of the high level of variability between studies and the low quality of the evidence (see [Figures S6](#pmed.1001619.s006){ref-type="supplementary-material"}--[S13](#pmed.1001619.s013){ref-type="supplementary-material"}). For experimental hut trials, similar conclusions are drawn from the sensitivity analyses and primary analyses ([Table S9](#pmed.1001619.s032){ref-type="supplementary-material"}; [Figures S14](#pmed.1001619.s014){ref-type="supplementary-material"}--[S20](#pmed.1001619.s020){ref-type="supplementary-material"}).

Discussion {#s5}
==========

The study set out to determine whether mosquito resistance to insecticides is having an impact on entomological outcomes in ITNs compared to UTNs in three experimental settings: highly controlled cone studies, laboratory tunnel studies with animal bait, and field trials in huts with humans as the attractant. Cone tests for mosquito knock-down showed reduced levels of knock-down associated with higher levels of resistance. Laboratory tunnel test results demonstrated a reduced effect of ITNs in mosquitoes with higher levels of resistance in terms of blood feeding, mosquito mortality, and passage through the nets.

In experimental hut trials the RD for mortality for ITNs compared to UTNs showed that ITNs continued to have an effect in all categories of resistance. The meta-analytic results showed that the difference in mortality risk using ITNs as compared with UTNs modestly decreased as resistance increased, and the test for subgroup differences demonstrated a difference in the RD between high, medium, and low resistance subgroups. The substantive heterogeneity in the studies\' results and design may mask the true relationship between resistance and the RD, and the results need to be interpreted with caution.

What is clear from the results is that ITNs continue to have a substantive effect compared to UTNs in many studies, and that despite best efforts, explaining the heterogeneity between studies has been problematic, with field studies showing quite varied results. Sometimes there are quite unexpected and inconsistent findings such as in the study by Okumu et al. [@pmed.1001619-Okumu2], which shows no evidence of a benefit of insecticide despite bioassays indicating "sensitivity". Studies overall are very poor in characterising the resistance pattern of the mosquitoes, and the classification systems are unclear and lack uniformity.

We observed a large amount of heterogeneity and bias across studies, which was particularly acute in the field studies. Variations in the wild mosquito populations---such as their resistance levels, age, blood feeding and mating status (factors that themselves could influence resistance levels and host-seeking behaviour)---and also the local environment cannot be controlled for across studies. In addition, the execution of the field trials was not uniform across the studies, e.g., washing of nets, rotation of nets/sleepers, season in which the trial took place, length of the trial, decontamination of huts, and exclusion of male mosquitoes from the analysis. Only one field trial conducted a direct comparison of susceptible versus resistant mosquitoes [@pmed.1001619-Chandre1]. Deterrence could not be measured because the mosquitoes were directly placed inside the huts. For the remaining studies we conducted indirect comparisons between trials of nets in areas of high or moderate resistance and those in low resistance areas. Blinding of mosquito collectors, observers, and sleepers was not addressed in any of the studies.

One area of concern is that assessment of resistance of mosquito populations is not optimised across studies, and hence misclassification of resistance is likely to occur, adding to the high levels of heterogeneity. It is possible that target-site and metabolic resistance exert a differential impact on LLIN effectiveness, but most studies fail to accurately assess the presence of metabolic resistance. Insecticide resistance profiling of mosquito populations was varied across all studies, with just under half of the field studies measuring phenotypic resistance or *kdr* frequency, two out of the 14 studies measuring both, and only one measuring phenotypic resistance, *kdr*, and metabolic resistance [@pmed.1001619-NGuessan2]. Phenotypic resistance, as measured by bioassays, is regarded as the first step in identifying resistance [@pmed.1001619-World6]. It is prudent to always carry out bioassays to establish resistance levels before implementing mechanistic studies (e.g., genotyping for target-site and metabolic resistance and biochemical assays). It is unwise to assume that *kdr* alone is solely responsible for the resistant phenotype [@pmed.1001619-Brooke1],[@pmed.1001619-Donnelly1]; mosquitoes could still harbour metabolic resistance, for example. Based on this, we were reluctant to label mosquito populations with no or low *kdr* frequency as "susceptible" (low resistance).

It is becoming increasingly clear that metabolic resistance often underpins pyrethroid resistance in mosquitoes, as demonstrated by both gene expression studies of resistant populations [@pmed.1001619-Ranson1],[@pmed.1001619-Djouaka1],[@pmed.1001619-Awolola1],[@pmed.1001619-Muller1],[@pmed.1001619-Mitchell1],[@pmed.1001619-Irving1] and enzyme characterisation studies [@pmed.1001619-Stevenson1],[@pmed.1001619-Stevenson2]. To date, resistance has been directly implicated in operational control failure of pyrethroids only in *An. funestus* in South Africa [@pmed.1001619-Hargreaves1]. Metabolic resistance is the underlying mechanism [@pmed.1001619-Irving1],[@pmed.1001619-Wondji1],[@pmed.1001619-Amenya1], and therefore this mosquito species offers a unique opportunity to measure the impact of resistance on ITN efficacy. Unfortunately, none of the included studies have included the resistant form of this species.

A large number of studies were excluded because the insecticide resistance status of the wild mosquito populations was not characterised at the time of the study, but rather relied upon retrospective data. Mosquito populations are dynamic, and although a *kdr* frequency of \>0.90, which is close to fixation, is unlikely to revert rapidly, we cannot rule out the migration of mosquito populations or other confounding factors that could dramatically influence mosquito populations and/or resistance profiles over time.

In terms of interpreting the patterns, this has to be done with care, given the variability of the results. Reduced killing of mosquitoes with increasing resistance in tunnel and hut studies raises concerns. Feeding preferences of mosquitoes can be plastic [@pmed.1001619-Bonizzoni1], and there is evidence that anthropogenic species such as *An. gambiae* and *An. funestus* can switch to feeding on cattle to obtain a blood meal in the presence of pyrethroid-treated materials [@pmed.1001619-Dabire1],[@pmed.1001619-Githeko1]. So, although the personal protection properties of ITNs (i.e., prevention of blood feeding and induced exophily) are still maintained, there is still the risk that if different hosts are available, mosquitoes could adapt their feeding preferences and thereby maintain large population sizes. If LLIN coverage is lowered, nets become badly damaged, are inappropriately used, are sold on, or are used less over time (all of which are realistic scenarios) [@pmed.1001619-World7], the reduced killing of resistant mosquitoes, which may have obtained a blood meal elsewhere, could be a cause for concern.

Inconsistency between studies in relation to study design, execution, and reporting format across all experimental hut trials is an obstacle in addressing the relationship between resistance and ITN efficacy confidently. There are no clear guidelines for measuring ITN efficacy against resistant mosquitoes. As a consequence, the studies do not easily lend themselves to meta-analysis, and so it is difficult to generate a consensus. It is likely that the effects of resistance on some outcomes may be moderate or small, but the lack of standardisation means the methodological differences between studies obscure any detection or coherent synthesis between studies. So, if this field of research aims to identify generalisable findings, then researchers need to consider how best to measure the dependent and independent variables so that the results are more comparable. Our concern with this lack of transparency and standardisation, and the need for improved reporting, echoes recent calls [@pmed.1001619-Ioanndis1] for research to be better planned, co-ordinated, and of higher quality. With such gaps and lack of standardisation in the primary studies, it could be argued that current research represents inefficient use of scarce resources of the scientific community as a whole.

Based on the studies included in this meta-analysis, ITNs remain at least somewhat effective against African anopheline mosquitoes even when resistance has developed. However, whether ITNs remain effective against resistant mosquitoes cannot be definitively addressed whilst the execution and reporting of field studies and the profiling of resistance in mosquito populations is inadequate and inconsistent. Ideally, phenotypic resistance, target-site resistance, and metabolic resistance testing should all be applied to mosquito populations in the vicinity of the hut trial. If this is not feasible, then a combination of either phenotypic and target-site resistance testing or target-site and metabolic resistance testing should be performed. Authors should make it clear in their reporting if they have omitted to test for any of the three categories of resistance highlighted above. It is also imperative that resistance is measured at the time of the study rather than relying on retrospective data. International agreement is needed for standardised methods for measuring the impact of resistance on ITNs before conclusive statements about the effect of resistance can be made. In order to initiate dialogue about the standardisation of methods and reporting we have generated a list of criteria that need to be addressed based on the experience of this review ([Box 2](#pmed-1001619-box003){ref-type="sec"}). It is important that policy makers and non-governmental organizations plan vector control strategies and purchase ITNs based on the best available data.

Box 2. Considerations for Experimental Hut Study Design and Reporting {#s5a1}
---------------------------------------------------------------------

### Resistance Testing of Mosquito Populations: Reporting Information Required {#s5a1a}

-   Phenotypic resistance: doses of insecticide tested, exposure times to insecticide, total number of mosquitoes tested, total number of mosquitoes killed

-   Target-site resistance: type of mutation screened for (i.e., L1014F or L104S), associated *kdr* allele frequencies

-   Metabolic resistance: identification of genes or enzyme class implicated in conferring resistance

### Study Design Reporting Criteria: Reporting Requirement {#s5a1b}

-   Study start date: date

-   Study duration: number of nights

-   Mosquito species present at location: species name and molecular form

-   Nets randomly allocated to huts at start of trial: yes or no

-   Nets rotated between huts during trial: yes or no

-   Sleepers rotated between huts during trial: yes or no

-   Washing of nets: wash procedure provided

-   Huts cleaned between rotations: yes or no

-   Observers collecting mosquitoes blinded to intervention: yes or no

-   Sleepers blinded to intervention: yes or no

-   Male mosquitoes used in the analysis: excluded or included

-   Raw data for measured outcomes: provided

-   Raw data for UTNs: provided

Supporting Information {#s6}
======================
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CTN

:   conventionally treated bed net

ITN

:   insecticide-treated bed net

*kdr*

:   knock-down resistance
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:   risk difference

UTN

:   untreated bed net

WHO

:   World Health Organization
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